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ABSTRACT 
Nathan Paul Oien: Erythrocyte Carriers: Tool Development for Erythrocyte 
Mediated Diagnostic and Drug Delivery 
(Under the direction of David S. Lawrence) 
 Carrier erythrocytes have become increasingly popular in literature and in the 
clinical setting due to their low immunogenic response, ease of use, and well 
defined structure and physiology.  Small molecules, therapeutic proteins, and optical 
biosensors have each successfully been loaded into erythrocytes, establishing a 
strong methodological foundation for our work that utilizes erythrocytes as “carriers” 
of fluorescent biosensors and therapeutic agents. 
The initial stage of our research focused primarily on optimization of 
erythrocyte loading procedures using exogenous fluorophore labeled peptides and 
proteins (the term ‘loading’ refers to addition of exogenous material to the cytosol of 
erythrocytes). We visualized loading using widefield and confocal fluorescence 
microscopy. Upon our establishment of an optimized erythrocyte loading method, 
we used photo responsive cassettes to investigate whether erythrocytes can be 
manipulated to contain the cassette, and that upon microscope-mediated photolysis 
a fluorescence increase (without significant leakage) is observed.  
With the successful development of our erythrocyte loading method, we next 
sought to determine whether such innovative technology could be utilized to monitor 
endogenous kinase activity. Erythrocytes possess highly complex biochemical 
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pathways, which include enzymes important in glycolysis and maintenance of 
extracellular homeostasis. One of the most prominent enzymes in cells, including 
enucleated erythrocytes, is cAMP dependent protein kinase (PKA).  PKA in red 
blood cells is particularly relevant to the study of Malaria as it is a vital player in the 
protozoan parasite invasion of erythrocytes.[1] Thus, we proposed developing a 
method to monitor endogenous PKA activity in erythrocytes. This ability to monitor 
the endogenous PKA activity will be beneficial in assessing erythrocyte response 
during exogenous stimuli, serving as both a biological sensor and as a diagnostic 
tool to detect malarial invasion. We first aimed to monitor PKA activity through the 
development of a bi-molecular assay. Our innovative work demonstrates that the 
interaction between a positively charged peptide that is covalently bound to a far-red 
fluorophore and a negatively charged quencher that interacts with our labeled-
peptide results in quenched fluorescence. More importantly, our work demonstrates 
that after phosphorylation, the quencher is displaced and a fluorescence increase is 
observed. Upon verification of optimization and reproducibility, our carefully 
designed continuous assay was then used to monitor real-time endogenous PKA 
activity in erythrocyte lysates and within intact erythrocytes, the latter of which is 
possible through our established erythrocyte loading method.  
 With the completion of both our erythrocyte loading method and novel 
real-time detection of endogenous PKA activity, our next objective was to determine 
whether we could utilize erythrocytes for spatial and temporal- specific delivery of 
therapeutics using cobalamin-drug conjugates, where cobalamin acts as a light 
responsive photoprotecting group. In this instance, as opposed to intracellular 
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loading, we use lipids to anchor the drug conjugates to the exterior surface of the 
erythrocyte membrane. To test drug release from membranes, we utilized near-
infrared (NIR) light to release anti-inflammatory therapeutics from the vitamin B12 
derivative, hydroxyl-cobalamin. Cobalamin is an organometallic compound 
containing a cobalt center surrounded by a corrin ring. The cobalt axial bound ligand 
is readily cleaved using light.  Interestingly, cobalamin also contains a modifiable 
hydroxyl sugar. We show by lipidating the hydroxyl sugar and attaching therapeutics 
to the cobalt axial bond, that we could anchor the complex to erythrocyte 
membranes. Furthermore, we demonstrated photo-release of axially bound 
therapeutics using 525 nm light. Lastly, we were able to extend the wavelengths of 
light-mediated delivery into the NIR region by introducing lipidated NIR fluorophores 
to the erythrocyte membranes. Excitation of the lipidated fluorophore led to 
photocleavage of the cobalt small molecule bond. 
 Using erythrocytes as carriers represents a simple and attractive method as a 
delivery tool. Our work demonstrates the utility of erythrocytes as carriers for 
delivering diagnostic tools and therapeutics that respond to light resulting in spatial 
and temporal control of delivery and activation.  
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Chapter 1 Utilizing Erythrocytes as Highly Advanced Carrier Vesicles for 
Diagnostic and Therapeutic Purposes 
 
Overview 
 
 Erythrocyte carriers represent a method to increase therapeutic drug 
delivery with demonstrated success in the clinic.[2] The therapeutic index of these 
drugs can be increased by using light to control delivery in a spatial and temporal 
manner.  Similarly, diagnostic agents can be delivered using erythrocytes and 
light could be used to initiate the diagnostic at a specific location. However, an 
important aspect in using erythrocytes as carriers of light-activated diagnostic 
and therapeutic agents includes developing tools that can respond to light that is 
within the appropriate wavelength range to allow penetration of tissue. The 
objective of my dissertation is to show that we have successfully developed 
substrates which are able to be carried by erythrocytes and which respond to 
light that operates within the optical window of tissue.  These agents demonstrate 
the potential for in vivo delivery and activation in a spatial and temporal manner.  
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Erythrocytes as carrier vesicles 
 
 
Erythrocytes were first discovered in the 1600s followed by a more 
complete characterization in  the 1800s,[3] with further understanding  of a 
seemingly single vital role in the human body as “sacks of hemoglobin” that  
deliver oxygen while simultaneously removing carbon dioxide. Erythropoiesis, the 
formation of erythrocytes, is heavily dedicated to the role of concentrating 
hemoglobin inside the “young erythrocyte” or erythroblast, which involves 
multiple levels of gene regulation of highly complex mechanisms.[4] 
Erythropoiesis elicits the eventual ejection of the nucleus and other intracellular 
organelles, such as the mitochondria, to make room for hemoglobin to support 
oxygen transport.[5] Hemoglobin, a porphyrin containing oxygen transport protein, 
constitutes 90% of the dry weight of a mature erythrocyte and has been shown to 
exceed 90% upon exclusion of membranes and membrane bound proteins.[6] 
Despite the large accumulation of hemoglobin, Zolla et al. performed a proteomic 
study that demonstrated evidence of 1,900 non-redundant proteins, suggesting 
the “sacks of hemoglobin” and corresponding microenvironment are more 
complex than originally believed.[6] Many of the aforementioned non-redundant 
proteins were found to be localized to the membrane and classified as integral 
membrane proteins; membrane-associated proteins, GPI-anchored proteins, and 
extracellular/cytoskeletal/membrane spanning proteins, all of which have widely 
varied functions including transport, binding, catalytic, signal transduction, 
glycolysis, structural and antioxidant activity.[7, 8] Many of these proteins are 
involved in protein protection such as glutathione peroxidase.[9] Interestingly, a 
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definitive property of erythrocytes, is their elasticity and deformability that is 
critical for the average 5 to 10 μm cell to pass through 3 to 5 μm vessels.[8, 10] 
Elasticity and deformability involves many of the previously mentioned protein 
classifications. In fact, loss of elasticity and deformability in erythrocytes over the 
120 day life cycle corresponds with eventual degradation and clearance of the 
erythrocyte.[11]  As a result it is important to use fresh erythrocytes when studying 
or using erythrocytes to ensure ‘normal’ phenotypes are observed.  
When comparing erythrocytes to other carriers such as liposomes or 
nanoparticles that are short lived in the body (days to weeks) and accumulate in 
the liver,[12] the long (120 day) life cycle and ability to circulate through blood 
vessels located throughout the body make erythrocytes an attractive target as 
carriers of therapeutics and diagnostics. Since the 1950s, large efforts have been 
put forth to utilize erythrocytes as a vessel to carry and deliver exogenous 
substrates in vivo. In 1979 such methods of loading erythrocytes with exogenous 
substrates for in vivo use were termed ‘carrier erythrocytes’ and have 
subsequently been further developed. Examples of erythrocyte mediated delivery 
of diagnostic tools, small molecule therapeutics, and even proteins are described 
in the literature.[13]  Two primary carrier mechanisms with exogenous substrates 
have been utilized thus far (Figure 1.1) 1) binding to the extracellular membrane 
of erythrocytes through antibody recognition of erythrocyte surface proteins, 
covalent modification of the extracellular membrane, or use of hydrophobic lipids 
to anchor substrates to the membrane; or 2) loading into erythrocytes by altering 
isotonicity and inducing formation of small pores in the erythrocyte membrane. In 
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fact, combined basic and translational research efforts utilizing these two 
erythrocyte carrier methods have yielded promising therapies that are currently in 
all three phases of clinical trials for the treatment of cancer and inflammation 
related diseases.[13] 
 
   Figure 1.1 Loading methods of erythrocytes used as carriers.  Proteins and small molecules 
can be loaded into erythrocytes (left) or bound to the extracellular surface via membrane protein 
targeted antibodies (right) or through chemical modification of erythrocyte membranes.
[3]
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Erythrocyte carriers: membrane bound delivery systems 
 
The first erythrocyte carrier mechanism involves membrane bound 
delivery. The erythrocyte membrane is comprised of protein (52%), lipids (40%), 
and carbohydrates (8%),[14] the abundant availability of proteins and lipids serve 
as ideal targets for efficient membrane bound delivery mechanisms of 
erythrocyte carrier vesicles.  
Protein-bound targeting via antibodies: Drug delivery via a membrane 
bound delivery system may be mediated by an antibody drug conjugate that 
targets erythrocyte membrane proteins.  The erythrocyte membrane proteins are 
categorized into two subgroups, peripheral membrane proteins and integral 
membrane proteins. Integral membrane proteins are located at the cytoplasmic 
side of the erythrocyte membrane and are currently of not much utility for 
membrane bound delivery systems which use antibodies. Integral membrane 
proteins are tightly bound to the membrane and span both sides of the 
erythrocyte membrane exposing protein extracellularly and intracellularly, and 
thus serve as ideal membrane bound delivery target components. Specifically, 
band 3 and glycophorins are two major integral membrane proteins of 
erythrocytes that have been utilized as targets for drug delivery methods via 
antibody targeting mechanisms.[15, 16] Using glycophorin as a delivery target has 
been described to treat delayed cerebral ischemia (DCI) in mice (Figure 1.2).[17] 
By targeting glycophorin A with an antibody (anti-glycophorin A)-urokinase (a 
type of tissue-type plasminogen activators) derivative, the detrimental microclot 
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burden was reduced in mice during subarachnoid hemorrhage. Murciano et al. 
recent findings suggest modifying erythrocytes to carry urokinase (via 
glycophorin A targeting) specifically localized the thrombolytic agent to dissolve 
clots that may have the potential to cause cerebral ischemia, thus serving as a 
therapeutic agent to reduce DCI.[17]    
 
Figure 1.2 Antibody-urokinase conjugates bind to erythrocytes and target urokinase activity 
to hemorrhage site. A) High doses of Urokinase required for reperfusion and diffusion of urokinase 
into occlusive pathological clots increases the risk of bleeding. B)  Antibody-mediated targeting of 
urokinase to erythrocytes reduces the clearance rate of urokinase and increases specificity for 
potentially harmful clots. (Uk urokinase, P plasminogen, AP Plasmin).
[18]
 
 
 
 
Chemically-induced targeting: Another strategy for membrane based 
erythrocyte delivery systems is to manipulate the erythrocyte membrane by 
chemical means, such as through covalent modification. Covalent modifications 
of membranes is advantageous as a delivery system as it provides permanent 
modifications to the cell (until cleared), as well as elimination of antibody cross-
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reactivity in vivo and eliminating the need for erythrocyte membrane protein 
target identification. However, chemically-induced targeting also has potential 
pitfalls since covalent modification requires ex vivo manipulation of erythrocytes 
and use of chemical crosslinkers to modify the surface with the potential to 
damage and reduce integrity of erythrocyte membranes.[18]  Techniques for 
crosslinking molecules to erythrocytes  have been developed since the 1950s, 
utilizing crosslinking agents, such as cyanuric chloride,[19] N-hydroxysuccinimide  
(NHS),[20] trypsin and phenylhydrazine,[21] N-ethylmaleimide (NEM),[22] and 
glutaraldehyde.[23] Polyethylene glycol (PEG) modification of erythrocyte 
membranes using cyanuric chloride has been shown to camouflage erythrocyte 
antigenic determinants, such that loss of carbohydrate blood-type specific “ABO” 
groups and HLA typing on the surface of erythrocytes allowed for interspecies 
transfusion with sufficient erythrocyte lifespan.[19] The clinical significance of 
PEGylating erythrocytes for transfusion suggests blood could be used from any 
donor, and thus eliminating the need for blood-type matched donors.  Similar to 
PEG modification, NHS ester modification of erythrocyte membranes has also 
demonstrated success.[20] Covalent crosslinking of biotin via NHS ester 
modification provides a versatile arm that can be used to attach anything, via a 
streptavidin handle, from small molecules and peptides to large enzymes.[24] 
Under monovalent conditions tissue-type plasminogen activator (tPA) (used to 
dissolve nascent clots) has been attached to erythrocyte surfaces. tPA attached 
to the membrane of erythrocytes was demonstrated to have an increased 
lifespan (versus tPA alone) and function to reduce pulmonary clots in a rat 
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venous thrombosis model.[17] Despite a propensity to cause lysis, as 
demonstrated by the mouse studies performed by Scott et al., covalent 
modification of erythrocytes remains a strong possibility for clinical use. 
Lipid targeting: Exogenous lipids serve as another candidate for an 
efficient membrane bound delivery mechanism of erythrocyte carrier vesicles. 
The erythrocyte membrane is comprised largely of lipids, specifically: 
phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylethanolamine (PE), 
and phosphatidylserine (PS), as well as smaller fractions of phospholipids 
phosphatidic acid, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4, 
5-diphosphate.[14] These phospholipids, along with the membrane associated 
proteins and carbohydrates, form the erythrocyte membrane bilayer is comprised 
of a hydrophobic interior and a hydrophilic exterior. Specifically, lipids such as PC 
or PS have been used to anchor small molecules to the erythrocyte membrane 
with minimal impact on erythrocyte biology. For example, PC has been used to 
anchor the mitochondrial tracker boron-dipyrromethene (bodipy) and biotin to 
erythrocyte membranes.[25, 26] Muzykantov et al. compared lipid targeting via PE-
biotin bound to the membranes of erythrocytes to chemically-induced targeting 
via covalently bound NHS-biotin loaded erythrocytes, both methods reported 
similar amounts of avidin. Importantly, they did not observe erythrocyte lysis 
when anchoring biotin to erythrocyte membranes using PE.[25] Muzykantov et al. 
findings represent a potentially simplified option for membrane-bound delivery 
targeting of erythrocyte carrier methods over covalent modification. 
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In summary, chemically-induced and exogenous lipid targeting strategies 
of membrane bound delivery mechanisms show promise for using erythrocytes to 
deliver therapeutics. The 120 day erythrocyte lifespan, reduced immune 
response, and the myriad of tools available for membrane anchored delivery 
contribute to the attractiveness of this technique for therapeutic delivery. 
Membrane bound delivery systems have the potential to enhance therapeutics by 
enhancing their circulation lifespan while maintaining therapeutic potency.  
 
Erythrocyte carrier delivery strategies: intracellular loading 
 
A second erythrocyte delivery mechanism involves intracellular loading. 
Loading requires the removal and isolation of blood from the body. Due to the 
high hemoglobin content (90%), erythrocytes are easily separated by 
centrifugation,[27] allowing for ease of blood cell separation. Over the past 60 
years, since the first published erythrocyte loading method, many have been 
developed to load erythrocytes; methods should be used that minimize alteration 
to erythrocyte phenotypes if erythrocytes are to be used in vivo. A few of the 
most common erythrocyte loading methods include osmosis-, electroporation-, 
and endocytosis-based methods. 
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Figure 1.3 Loading erythrocytes using hypotonic swelling. The “cargo” intended to be loaded is 
mixed with erythrocytes in an isotonic buffer. The mixture is then mixed with a low salt solution to 
induce swelling and pore formation. Isotonicity is then restored to induce sealing.  
 
Osmosis:  The first method for loading erythrocytes uses osmosis, by 
which manipulations to induce a hypotonic solution causes erythrocyte swelling 
and formation of pores, allowing for cargo to be loaded.  Osmosis based 
methods for efficient erythrocyte loading of proteins, small molecules, or drugs 
have been common methods utilized during investigations of drug delivery 
efficiency, membrane protein analyses, and phenotypic analyses of erythrocyte 
function.[3, 13, 18, 28, 29] Although erythrocyte osmosis-based loading methods may 
be further subcategorized into 5 classifications (hypotonic dilution; hypotonic 
dialysis; hypotonic pre-swelling; osmotic pulse; and hypotonic hemolysis),[27] 
each classification follows a similar process.  Erythrocytes are exposed to a 
hypotonic solution, by which the low salt solution in the buffer induces rapid water 
influx; this, in combination with the slow salt efflux, causes the erythrocytes to 
“swell”. As erythrocytes cannot alter the surface area of their membrane, 
increasing the internal volume induces a single pore to form in each 
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erythrocyte.[11] Pore formation allows for the free exchange of cargo between the 
erythrocyte cytoplasm and the extracellular environment.[11, 30] When isotonicity is 
restored the pore begins to reseal. Where typical cells would undergo apoptosis 
in similar conditions, erythrocytes do not contain the machinery (mitochondria or 
nucleus) to induce apoptosis and have been shown to be stable for up to 3 
months after loading.[5, 28, 31] Hypotonic dilution and hypotonic dialysis are the two 
most common forms of erythrocyte loading and will be highlighted here, for 
information on the other loading methods refer to Magnani et al. Although both 
hypotonic dilution and dialysis methods can be readily established in any 
laboratory, hypotonic dialysis is the most common method with well-established 
optimization protocols and documented stable biochemical and physiological cell 
characteristics.[32] In brief, loading erythrocytes with hypotonic dialysis requires 
the use of dialysis kits placed in solutions with specific osmotic pressure to 
ensure minimal perturbation of erythrocyte physiology. However, this requires a 
large amount of substrate relative to erythrocyte volume. In contrast, hypotonic 
dilution mediated erythrocyte loading simply requires dilution of erythrocytes in a 
hypotonic solution until lysis begins to occur, followed by restoration of isotonicity 
and incubation, requiring minimal substrate concentrations.[33] Though hypotonic 
dilution may not maintain optimal physiological properties of erythrocytes as well 
as hypotonic dialysis methods do; the simplicity of this method, and minimal 
substrate utilization, has made this an attractive loading method. Osmosis-based 
erythrocyte loading has been utilized to load doxorubicin as a method of drug 
delivery.[34, 35] Doxorubicin is an extremely cytotoxic small molecule antibiotic that 
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is used as a chemotherapeutic agent.[36] To maximize efficacy and reduce 
cytotoxicity doxorubicin should be delivered in small doses over many increments 
of time.[37] De Flora et al. showed erythrocytes were able to be loaded with high 
concentrations of doxorubicin. Furthermore, doxorubicin was protected from 
semiquinone formation, the semiquinone is thought of as the active form and 
generates ROS inducing DNA damage. Doxorubicin loaded erythrocytes were 
efficient in the slow release of unaltered doxorubicin in the vascular system.[34] 
Clinical investigations of lymphoma patients treated with doxorubicin-loaded 
erythrocytes, in comparison to the normal delivery method of free doxorubicin, 
showed reduced doxorubicin clearance, lack of severe myelosuppression, and 
no evidence of cardiotoxicity.[35] Though further studies are warranted to 
determine the efficacy of this treatment compared to slow intravenous infusion, 
the preliminary clinical results demonstrate a safer drug delivery method of a 
typically strong cytotoxic drug over previous free, normal delivery methods. 
 
Figure 1.4 Loading erythrocytes using electroporation. Erythrocytes are mixed with isotonic 
saline containing “cargo” to be loaded and electroporated for a brief time followed by recovery. 
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Electroporation:  A second method for loading erythrocytes involves 
electroporation. Through electroporation electric field pulses are applied to 
erythrocyte suspensions altering membrane integrity and increasing permeability, 
allowing for a potential loading method.[38] During electroporation, erythrocytes 
are suspended to 10-20% hematocrit in an isotonic saline solution buffer 
containing iso-osmotic concentrations of sucrose and the desired cargo to be 
loaded into the erythrocyte.  When the electric field is applied, this induces 
breakdown of the erythrocyte membrane and allows the cargo to become 
encapsulated. After the sub-millisecond electric pulse the erythrocytes are 
incubated at 37 °C to stabilize or “reseal” the membrane.[39] Previous work 
established that electroporation-based erythrocyte loading via electric pulses 
should not exceed 2.5 kV/cm in order to minimize lysis, and erythrocytes 
incubated at 4 °C for 1 h allowed loading, and  approximately 10 min at 37 °C 
allowed membrane resealing.[40] Interestingly, Flynn et al. demonstrated 
erythrocytes could be loaded with methotrexate using electroporation and 
subsequent photosensitization with light exposure resulted in release of 
methotrexate from erythrocytes,[41] suggesting erythrocytes loaded with 
anticancer drugs and photosensitized may be a potential strategy to treat cancer 
via photodynamic therapy (PDT).[42] Loading cytotoxic agents into erythrocytes 
and using light to induce spatially and temporally selective release of the drug 
near the tumor microenvironment could provide an alternative method to deliver 
anticancer agents at a high concentration to improve therapeutic efficacy while 
reducing host cytotoxicity.  
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Figure 1.5 Loading erythrocytes by endocytosis. Erythrocytes are mixed with “cargo’ to be loaded 
and agents that induce endocytosis. After membrane invagination and sealing the “cargo” escapes 
the endosome and become cytosolic.  
87 
Endocytosis: A third type of erythrocyte loading involves endocytosis. 
Endocytosis is the natural cellular process of invagination of the plasma 
membrane to uptake extracellular fluid and components in the cell. Once the 
external surfaces of the cell wall closes, an intracellular bi-layered vesicle is 
formed, housing the extracellular fluid and components, including proteins, small 
molecules, and/or drugs.[39] Interestingly, the ability of the erythrocyte to 
endocytose is inversely correlated with erythrocyte age.[43] Amphipathic cations 
(vitamin A, chloropromazine, primaquine) and small hydrophobic molecules 
(steroids) can induce endocytosis in cells.[44, 45] Molecules that are not naturally 
endocytosed by erythrocytes can be mixed with amphipathic cations, providing a 
potentially universal mechanism for loading. Endocytosis-mediated loading of 
erythrocytes has been successfully applied by using hydrocortisone, vinblastine, 
and chlorpromazine.[46]  Endocytosis-mediated loading of erythrocytes is a 
particularly attractive strategy since it offers the least perturbation to erythrocytes, 
absence of lysis or loss of cytoplasmic content, and an increased overall lifespan 
(maximizing the 120 day lifespan of erythrocytes). Specifically, pravastatin was 
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demonstrated to be intracellularly carried by erythrocytes via endocytosis-
mediated loading, which may serve as a slow release formulation for the 
potential treatment of many diseases including stroke and Alzheimer’s disease.  
Typically patients receiving pravastatin experience side effects, such as diarrhea, 
constipation, nausea and indigestion. Due to the low oral bioavailability and 
subsequent requirement for increasing the dosage side effects on the liver, 
kidney, and muscular tissue may be exacerbated.[47, 48] Endocytosis-mediated 
loading of erythrocytes with subsequent drug release may provide an alternative 
delivery method to oral delivery. Harisa et al. determined that pravastatin, as an 
amphipathic cation, was able to be loaded via endocytosis into erythrocytes with 
minimal perturbation. Furthermore, they were able to monitor the slow release of 
Pravastatin with 70% release over 24 h.[48] This prolonged ability to circulate in 
vivo, provides an efficient slow release of loaded agents, allowing highly cytotoxic 
compounds, such as anticancer agents to be delivered while minimizing host 
cytotoxicity typically observed via oral route delivery.  A major pitfall to 
endocytosis based loading methods is that not all therapeutics can be loaded in 
this manner. However, it has been demonstrated that even large substrates, 
such as DNA, can be entrapped in erythrocytes via endocytosis and used to 
deliver to other cells using fusagens such as PEG.[49]  
 The general practice of loading therapeutic agents into the intracellular 
environment of erythrocytes represents an attractive method for drug delivery. 
The loading process is simple, fast, and provides consistent results. The cargo 
loaded into erythrocytes experiences increased circulation lifetime as a result of 
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being protected from the extracellular environment. Furthermore, the slow 
release of cytotoxic agents can reduce experienced side effects and provide 
better treatment options.  
 
Erythrocyte carriers: diagnostic assays 
 
Current diagnostic-based assays include removing erythrocytes from the 
patient and testing properties, such as: sedimentation rates for inflammation and 
infection,[50] loading erythrocytes with contrast agents to assist in MRI,[51, 52] and 
using antibodies to monitor erythrocyte changes by enzyme-linked 
immunosorbent assay (ELISA) or flow cytometry.[53] None of the current tests 
utilize erythrocyte based enzymatic activity as reporters for disease. Developing 
an assay to monitor endogenous erythrocyte enzyme activity could allow for 
rapid detection of disease in vivo. As previously described, erythrocytes contain 
many biochemical pathways that are all dependent on response to external 
stimuli. Erythrocytes have been defined as oxygen sensors, which are capable of 
responding to various oxygen concentrations and altering blood flow to match 
metabolic needs.[54] Erythrocytes entering a region with high oxygen demand 
release ATP and subsequently induce localized vasodilation.[55] Similarly, nitric 
oxide (NO) may impact the activity of a G-protein coupled receptor (GPCR) Gi, a 
transmembrane receptor within the erythrocyte membrane, through stimulation of 
endogenous mono-ADP-ribosyltransferase to inhibit ATP release and 
subsequent calcium uptake and release of epoxyeicosatrienoic acids (EETs) for 
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vasodilation.[56, 57] On the infectious disease side, malaria has been shown to 
invade erythrocytes and destroy endogenous proteins and utilize its own proteins 
to replicate, thereby perturbing the response of erythrocyte proteins to 
extracellular stimuli.[58, 59] Therefore, developing an assay to monitor erythrocyte 
enzymatic responses to external stimuli could provide diagnostics for 
cardiovascular disease and erythrocyte parasitic infection.  
 
Optical window of tissue 
 
Hemoglobin, melanin, and water are the primary components in biological 
tissue substrates that impact the therapeutic and diagnostic capabilities of light. 
Penetration of tissues by short wavelength light is hindered by hemoglobin and 
melanin, thus blocking either the fluorophore dependent response (as needed by 
a diagnostic) or providing enough energy to activate a light responsive 
therapeutic.[60] Longer wavelength light (>950 nm) is unable to penetrate tissue 
due primarily to water absorbance. However, between the hemoglobin/melanin 
absorbance and water absorbance there is an absorbance minimum known as 
the optical window of tissue, which resides between 600 and 950 nm (Figure 
1.6).[61] Therefore, light used to probe tissue should be longer than 600 nm. As 
proof-of-concept  when a green light (~550 nm) or red light (~700 nm) from a 
laser pointer is held to human tissue (the finger), the red light within the optical 
window is able to be visualized through a finger while this is not the case for 
green light. The small optical window is one of the primary constraints preventing 
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the application of many currently developed enzymatic assays as useful 
diagnostics or drug delivery tools; therefore, our work aims to elucidate potential 
manipulation of tools for use within the optical window to be used in the 
development of diagnostic assays and drug delivery systems. 
 
Figure 1.6 Optical window of tissue. The optical window of tissue, shown in pink, occurs at the 
combined minimum of water, hemoglobin, and melanin. reprinted with permission from the 
publisher.
[61]
 
 
 
The optical window of tissue is separated into three subgroups: red, far-
red, and NIR light. While there is not a specific recognized spectral cutoff for 
each of these sections, for the purposes of this dissertation; red light is defined 
as 600 - 710 nm, far-red light as 710 - 850nm, and NIR light as 850 - 1100 nm. In 
silico data demonstrate fluorescent probes for diagnostic purposes require the 
use of far-red fluorophores to penetrate a majority of tissue types. For example, 
Figure 1.7 shows the results of a simulation of tissue penetration of Cy5.5, a red 
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fluorophore, through various human tissue samples,[62] such as the lung. 
However, light that excites red fluorophores weakly penetrates other tissues, 
such as the dense tissues of breast and muscle. 
Figure 1.7 Signal loss of Cy5.5 in various tissue samples. Expected signal loss of fluorophore 
Cy5.5 (Ex: 673 nm Em: 704 nm) in various tissue samples reprinted with permission from the 
publisher.
[62]
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Selection of long wavelength fluorophores 
 
The optical window for penetration of tissue coincides directly with the 
absorbance minimum of hemoglobin (Figure 1.6). As previously described, 
erythrocytes are the primary carriers of hemoglobin in tissue.[6] Therefore, we 
propose erythrocytes and their respective lysates as model systems for the 
development of diagnostic and therapeutic technologies through proof-of-concept 
demonstrations. We selected the fluorophores listed in Table 1.1 for use in an 
enzymatic assay to monitor intracellular kinase activity (Chapter 3) and for use in 
the light mediated delivery of anti-inflammatory agents (Chapter 4). Table 1.1 
fluorophores were selected since they are within excitation wavelengths of the 
red and far-red regions, commercially available, and possess large extinction 
coefficients. Fluorescein, Cy3, and tetramethylrhodamine (TAMRA) are the only 
exceptions to the above statement, TAMRA and Fluorescein were used as a 
control to demonstrate the necessity for longer wavelength fluorophores. 
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Table 1.1 Various fluorophores for visualization within the optical window of tissue.
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Table 1.1 continued. 
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Fluorescence signal in erythrocyte lysates 
 
The concentration of erythrocytes in the blood stream is referred to as the 
hematocrit. Hematocrit concentrations/levels are determined by centrifuging a 
sample of blood and calculating the ratio of the red zone (erythrocytes) to all 
other zones. The average human hematocrit is between 30 - 70%. The higher 
the hematocrit the more the hemoglobin absorbance will interfere with 
fluorescent assays. The impact on the fluorescent response is proportional to 
how much the fluorophore excitation peak overlaps with the hemoglobin 
excitation peak. We hypothesize that overlaying the absorbance spectrum of 
erythrocyte lysates between 450 nm and 700 nm (the tailing peak of hemoglobin 
absorbance) with the absorbance spectrum of five fluorophores (FAM, TAM, 
Atto620, Atto633, and Atto680) may identify that fluorescein and 
tetramethylrhodamine should experience more interference due to hemoglobin 
(Figure 1.8); in contrast to Atto633 or Atto680, which we predict will have 
minimal overlap with the absorbance of hemoglobin and may provide much 
better signal response in solutions containing erythrocytes. The reduced signal 
loss experienced by red and far-red fluorophores is supported by the results 
provided within Figure 1.9. Fluorescein and tetramethylrhodamine TAMRA 
signals are nearly abolished when measuring fluorescence through 10% 
hematocrit lysates and completely undetectable at 100% hematocrit lysates. 
However, Atto633 provides significant fluorescence signal even in 100% 
hematocrit lysates.  
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Figure 1.8 Erythrocyte lysate absorbance vs fluorophore absorbance Erythrocyte lysate 
absorbance (red) compared to FAM, TAMRA, Atto 620, Atto633, and Atto 680 labeled peptide. 
Reprinted with permission from the publisher.
[63]
 
 
   
Figure 1.9 Signal loss of fluorophores due to various hematocrits of erythrocyte lysates. 
Signal loss of FAM, TAM, and Atto633 labeled peptide in 0, 10%, and 100% hematocrit lysed 
erythrocytes. Reprinted with permission from the publisher.
[63]
 
  
25 
 
Conclusion: research aims  
 
 In vivo clinical use of erythrocyte carriers for diagnostic assays or light-
dependent delivery of therapeutics requires the development and optimization of 
model systems that may utilize light capable of penetrating human tissues while 
also eliciting a spatially and temporally effective release-controlled response to 
such light, which is currently lacking.[64] Therefore, our research aims to fill this 
gap by developing a versatile diagnostic assay to monitor specific protein kinase 
A (PKA) enzymatic activity in erythrocytes since PKA is vital to the erythrocytes’ 
role in vasodilation and aberrant activity in disease, including sickle cell and 
malaria. In addition, we hypothesize that using erythrocytes as carriers of anti-
inflammatory therapeutics via membrane-bound loading methods may serve as a 
responsive therapeutic method for enhancement of drug delivery mechanisms. 
We aim to describe our work, which tests the following objectives; 1. 
Develop a method to load exogenous material into erythrocytes and use 
fluorescence microscopy to visualize loading and enzymatic activity and explore 
erythrocyte loading of small molecule therapeutics. 2. Develop an assay to 
monitor endogenous erythrocyte PKA activity. 3. Utilize erythrocytes as carriers 
of membrane-bound anchored therapeutics.  
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Summary:  
 
The next three chapters are dedicated toward the accomplishment of each 
objective. Specifically, Chapter 2 highlights my efforts in the development of an 
optimized erythrocyte loading method to load exogenous substrates and protect 
a protease substrate through membrane sequestration. In addition, within the 
subsequent chapters, I will highlight the main purpose of this dissertation which is 
to determine 1) whether PKA activity can be monitored in erythrocytes using red 
shifted fluorophores (Chapter 3); and 2) whether erythrocytes can be 
manipulated to serve as carriers of therapeutic agents (Chapter 4). Lastly, in the 
final chapter I end with a discussion of future directions and provide final remarks 
regarding my work.  
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Chapter 2 Method Development and Optimization for Loading Fluorescent 
Molecules into Erythrocytes 
 
Overview 
 
As previously described within Chapter 1, exposing erythrocytes to either 
electric field pulses or a hypotonic solution induces swelling and cellular 
membrane pore formation to aid effective exogenous substrate loading and thus 
form a “carrier erythrocyte”.  We investigated electroporation, hypotonic dilution 
and dialysis loading methods and found that hypotonic dilution offered fast, 
efficient, and consistent loading. Previous work utilizing the hypotonic dilution 
loading strategy has established successful loading of erythrocytes to carry a 
vast array of exogenous materials, such as proteins, small molecules, and 
therapeutic drugs;[3] therefore, our work focused on the development and 
optimization of the hypotonic dilution delivery strategy to load exogenous material 
that can be visualized in vitro by fluorescent microscopy. In addition, we aimed to 
establish a technique to monitor and visualize enzymatic activity as a means to 
develop a potential diagnostic assay. Specifically, we demonstrated erythrocytes 
can be loaded with a photolabile fluorescently quenched small molecule that 
becomes fluorescent upon stimulation with UV light, showing increases in 
fluorescence that can be detected and monitored over time using fluorescent 
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microscopy. We also demonstrated that the biological activity of loaded 
erythrocytes remains intact via enzymatic activity monitoring through a UV light-
activatable fluorescent protease reporter model system.  
In summary, our work is significant since we developed a novel, versatile 
system for efficient erythrocyte loading of exogenous material for in vitro 
monitoring of enzymatic activity, which may serve as a foundation for a potential 
method for erythrocyte loading of small molecule therapeutic and diagnostic 
agents. 
 
Introduction 
 
Erythrocytes have a unique metabolism different from all other cells due to 
their enucleated structure, thus allowing production of ATP exclusively through 
glycolysis with no mitochondria or gene expression involvement.[65] As such, 
erythrocytes are unable to undergo traditional apoptosis; instead erythrocytes 
rely on a series of pre-defined mechanisms utilizing macrophages for biological 
clearance in a process known as eryptosis. When erythrocytes are exposed to 
oxidative stress and/or injury, a cascade of signaling events elicits exposure of 
membrane phophatidylserine on the extracellular surface subsequently signaling 
for the recruitment of macrophages for the engulfment of damaged/aged 
erythrocytes.[66] Alternatively, erythrocytes may be cleared via IgG binding to 
band 3 leading to phagocytosis by macrophages within the liver.[67] In response 
to extracellular conditions that would normally induce lysis (osmotic shock, 
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exposure to high concentrations of DMSO, or high voltages) erythrocytes do not 
lyse. Instead, erythrocytes undergo physiological changes such as swelling and 
pore formation, which may be utilized to efficiently load exogenous material. 
Therefore, we utilized these methods for the development and optimization of a 
versatile method that can be utilized to reliably load exogenous material into 
erythrocytes. We compared the loading methods using various sized fluorescent 
molecules and evaluated the loaded erythrocytes using fluorescence microscopy.  
 Next, we sought to determine whether stimulating the light-sensitive 
dimethoxynitrobenzyl group with UV light may be accomplished within 
erythrocytes. We sought to address the question using a UV light responsive 
small molecule pro-fluorescent cassette.[68] Using this cassette we compared 
photolysis in the presence and absence of hemoglobin and determined 
photolysis conditions necessary for cleaving the nitrobenzyl group. We later used 
the established photolysis conditions to demonstrate that the nitrobenzyl groups 
can be used to prevent enzymes from modifying our substrate until light 
stimulation. 
 
Materials and Methods 
 
 Materials: All amino acids, NovaSyn TGR resin, 5-chloro-1-
[bis(dimethylamino)methylene]-1Hbenzotriazolium 3-oxide hexafluorophosphate 
(HCTU), 6-chloro-1-hydroxybenzotriazolen (6-Cl-HOBt) were obtained from 
NovaBiochem or Peptide International. 4 (1-(9 
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Fluorenylmethyloxycarbonylamino)ethyl]-2-methoxy-5-nitrophenoxy}butanoic 
acid (Fmoc-photolabile linker) and 3-Nα-Fmoc-Amino-3-(2-nitrophenyl) propionic 
acid (Fmoc-photolabile linker) were from Advanced ChemTech. N,N-
dimethylformamide (DMF), methylene chloride (CH2Cl2), magnesium chloride, 
10 X PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate dibasic, 
2 mM potassium phosphate monobasic and a pH of 7.4), and other general 
solvents were obtained from Fisher Scientific. N,N-diisopropylethylamine 
(DIEPA), 4-dimethylaminophenylazophenyl-4ʼ-maleimide (Dabcyl maleimide) , 
and dithiothreitol (DTT) were purchased from Sigma. Fluorescein-5-isothiocynate 
(5-FITC), were purchased from Invitrogen. 5-Carboxyltetramethylrhodamine (5- 
TAMRA, 4) was purchased from ChemPep. Peripheral erythrocytes were 
purchased from AllCells. Dialysis cassettes were purchased from VWR. 
 
Erythrocyte loading (hypotonic dilution): Fresh peripheral erythrocytes 
were washed 3x in 1x PBS containing 1 mM MgCl2 (centrifuging at 1,000 g for 3 
mins). After the final wash erythrocytes were re-suspended in 1x PBS containing 
1 mM MgCl2 to 10% hematocrit. 50 μL of washed erythrocytes was added to 450 
μL water containing substrates to be added. Erythrocytes were allowed to 
incubate on ice for 5 minutes and subsequently resealed by adding 50 μL 10x 
PBS containing 10 mM MgCl2 and incubation at RT for 30 minutes.  
 
Erythrocyte loading (hypotonic dialysis): Fresh peripheral erythrocytes 
were washed 3x in 1x PBS containing 1 mM MgCl2. After the final wash 
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erythrocytes were re-suspended in 1x PBS containing 1 mM MgCl2 to 10% 
hematocrit. Re-suspended erythrocytes were mixed with 1x PBS containing 
material to be loaded and added to a prepared dialysis unit (0.5 to 100 kD cutoff 
filter. The dialysis unit was then added to water and allowed dialyze for 4 hours at 
4 °C. The dialysis unit was then added to 1x PBS containing 1 mM MgCl2 and 
allowed to reseal at RT for at least 1 hour.  
 
Erythrocyte loading (electroporation): Fresh peripheral erythrocytes 
were washed 3x in 1x PBS containing 1 mM MgCl2. After the final wash 
erythrocytes were Re-suspended in 1x PBS containing 1 mM MgCl2 to 10% 
hematocrit. Re-suspended erythrocytes were mixed with 1x PBS containing 
material to be loaded and added to the electrode unit. Erythrocytes were then 
exposed to a brief 2.0 kV/cm2 pulse. The erythrocytes were then allowed to 
incubate (recover) at RT for 2 hours.  
 
Preparation of hemoglobin free ghosts (hypotonic dilution): Fresh 
peripheral erythrocytes were washed 3x in 1x PBS containing 1 mM MgCl2. After 
the final wash erythrocytes were re-suspended in 1x PBS containing 1 mM MgCl2 
to 10% hematocrit. Erythrocytes were then exposed to 10x volumes of deionized 
water and spun down at 16,000 g for 10 minutes. The supernatant was removed 
and the pellet was re-suspended in deionized water. The process was repeated 
until the pellet was white (generally 4 to 5 times). After the pellet turns white, the 
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supernatant was removed and the erythrocytes were re-suspended to 10% cell 
suspension in 1x PBS containing 1 mM MgCl2. 
 
Synthesis of fluorophore labeled PKA E. Coli containing PKA 
expression vector (described by Herberg et al.) was suspended in LB Broth and 
grown to OD of 0.6.[69] IPTG was used to induce expression. After expression 
and pelleting the cells were re-suspended in lysis buffer (30 mM MES, 1 mM 
EDTA, 50 mM NaCl pH 6.5) followed by incubation at 40 °C for 1 hour and 
subsequent lysis by sonication. The lysed cells were then centrifuged at 15,000 
RPM for 45 minutes at 4 °C. Purification was using a PII cellulose resin. Lysates 
were incubated in prepared PII cellulose resin overnight at 4 °C. The solution 
was then filtered. Then PKA was eluted off using running buffer (30 mM MES, 1 
mM EDTA, 5 mM DTT) and increasing concentration of KH2PO4 (from 100 mM to 
500 mM). The fractions were collected and analyzed by SDS-page for protein 
content at the expected molecular weight. Fractions containing expected band 
were pooled together. Atto-633 maleimide was used to label PKA. 5 mgs of 
Purified PKA was diluted in PBS buffer containing 1.3 equivalents of Atto-633 
maleimide was added to the solution and incubated overnight at 4 °C. Purification 
was performed by dialyzing (using a 10 Kd cutoff filter) against PBS overnight at 
4 °C.  
 
Synthesis of photolabile cassette (synthesis completed by and 
reprinted from Hsien-Ming et al.[68]). Fmoc-photolabile linker was used to make 
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the peptide backbone configurations on the TGR resin (0.2 mmol/g, 500 mg 
resin, 0.1 mmol scale). A standard peptide coupling protocol was used for the 
amino acid couplings including the Fmoc-photolabile linkers (Fmoc-DMNB). 
Amino acid (3 equiv/equiv resin), HCTU/6-Cl-HOBt (3 equiv/equiv resin) and 
DIEPA (8 equiv/equiv resin) were mixed with resin in DMF and reacted for 2 h at 
RT. Fmoc deprotection was achieved using 20% piperidine in DMF for 20 min at 
RT. The N-terminus was capped using acetic anhydride with 20% DIEPA for 20 
min. Following N-terminus acetylation, the Lys side-chain (ivDde) protecting 
group was deprotected using 2% hydrazine monohydrate in DMF (25 mL/g resin 
of hydrazine solution, 3 X 3 min). The backbone peptidyl resins was split in half 
(50 μmol scale) for the fluorophore labeling reactions.  For the 5-TAMRA 
labeling, 5-TAMRA (3 equiv, 150 µmol) was preactivated using HCTU (3 equiv, 
150 μmol) with DIEPA (8 equiv) in DMF for 1 min and reacted with the Lys 
deprotected peptidyl resins for 2 h. After the fluorophore labeling, the eight 
peptidyl resins were dried and subsequently cleaved in a solution of 95% TFA, 
2.5% H2O and 2.5% triisopropylsilane. The fluorophore-labeled peptides were 
HPLC (semiprepative C-18 column) purified using a linear gradient binary solvent 
system (solvent A: 0.1% TFA/H2O; solvent B: 0.l% TFA/CH3CN) with a ratio of 
A:B that varied from 80:20 (0 min) to 30:70 (30 min). The major fraction for each 
peptide was collected and freeze-dried. The eight individual peptides were 
dissolved in DMF (10 mM stock solution) and further aliquoted into 4 vials (400 
μL, 4 μmol each vial, total 32 vials) for the quencher labeling reaction The thiol-
reactive quencher (QSY-35 maleimide), (2 equiv, 8 μmol) was added to the vials 
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and the peptide/quencher mixtures further diluted to 1 mL with 50% DMF/ 50% 
PBS at pH 7.5, and reacted for 2 h to generate the final product. The final 
product was purified by HPLC (semiprepative C-18 column) using a linear 
gradient binary solvent system (solvent A: 0.1% TFA/H2O; solvent B: 0.l% 
TFA/CH3CN) with a ratio of A:B that varied from 80:20 (0 min) to 30:70 (30 min). 
The major fraction from each reaction was collected and characterized by 
ESIMS. The subsequently prepared DMF stock solutions employed the HPLC 
purified peptide. Peptide concentration was obtained by using (1) the extinction 
coefficient of the λmax of quencher or (2) the extinction coefficient summation of 
quenchers + fluorophores at the λmax of quenchers if there is an overlap between 
the fluorophore and quencher absorbance spectra: For TAMRA cassette, the 
concentration QSY 35 containing cassette was determined using only λmax 
QSY35 (24000 cm-1M-1 @ 476 nm). 
Figure 2.1 HPLC of the photolabile cassette. Photolabile cassette was purified using the following 
gradient: 80% solvent A/20% solvent B (0 min) to 30% solvent A/70% solvent B (30 min) to 10% 
solvent A/90% solvent B (40 min), The peptide cassette (P) and excess quencher (Q) are labeled in 
the chromatograms (characterized and confirmed by mass spectrometry). Reprinted with permission 
from the publisher
[68]
. Copyright 2010 American Chemical Society. 
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Synthesis of C18-protease substrate (synthesis of protease substrate was 
obtained from and described by Nguyen et al.[70]) 
 
Figure 2.2 Synthesis of lipidated protease sensor. Reprinted with permission from 
publisher
[70]
 
 
Standard solid phase peptide synthesis (SSPPS) was performed on a 
Prelude peptide synthesizer from Protein Technology using Fmoc-protected 
amino acids (amino acids 3 eq., HCTU 2.95 eq., DIPEA 10 eq. in DMF, double 
coupling in 20 and 40 min). Fmoc deprotection was performed using piperidine 
(25%) in DMF (3 times, 10 min each). The peptide containing a Lys side chain 
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protected with the acid sensitive 4 methyltrityl group (Mtt), Boc-
K(Fmoc)RRRLAALAAK(Mtt), was synthesized on a NovaSyn TGR resin using 
SSPPS. The Fmoc protecting group on the lysine residue was deprotected by 
piperidine (25%) in DMF followed by coupling of 5-Tam fluorophore using 5-Tam 
(1.5 eq.), HCTU (1.5 eq.), and DIPEA (10 eq.) in DMF for 4 h. The Mtt was 
removed with 1% trifluoroacetic acid (TFA) in CH2Cl2 followed by coupling 5-
Fam using 5-Fam (1.5 eq.), N,N′-diisopropylcarbodiimide (DIC, 1.7 eq.), and 1- 
hydroxybenzotriazole (HOBt, 10 eq.) in DMF for 2 h. The peptide was then 
cleaved from the resin with TFA:H2O:Triisopropylsilane in a ratio of 95:2.5:2.5, 
and purified by HPLC using H2O:CH3CN with 0.1% TFA to afford 3a. Solution of 
pure 3a was acidified with HCl and dried. C100H135N24O22
+. Exact mass calculated 
2024.02, found (ESI+) 675.3 (M + 2 H)3+, 506.6 (M + 3 H)4+, 405.6 (M + 4 H)5+. 
Synthesis of 4. Dried 3a (0.55 μmol) was redissolved in DMF (500 μL). DIPEA 
(5.5 μmol) and Ac2O (5.5 μmol) were added to the DMF solution containing 3a. 
The reaction mixture was shaken at room temperature for 1 h. H2O (500 μL) was 
then added and the mixture shaken for 30 min. Piperidine (27.5 μmol) was then 
added and the mixture shaken for 30 min. Solvent and excess reagents were 
removed under vacuum and the crude product purified by HPLC using the C18 
column to afford pure 4 (Figure 2.2). C102H137N24O23
+. Exact mass calculated 
2066.03, found (ESI+) 1033.6 (M + H)2+, 689.2 (M + 2 H)3+, 517.2 (M + 3 H)4+, 
414.0 (M + 4 H)5+. Synthesis of 5. 1 (21.5 mg, 33 μmol), HCTU (12.4 mg, 30 
μmol), and DIPEA (10.9 μL, 66 μmol) were dissolved in minimum amount of DMF 
(with a small amount of CH2Cl2 to help dissolve the compound) and the solution 
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was stirred for 2 min. The HCTU activated peptide was then added to DMF (20 
mL) containing 3a (22 μmol) and DIPEA (220 μmol). The reaction mixture was 
shaken at room temperature for 20 min. H2O (0.5 mL) was then added to the 
reaction mixture, which was then shaken for 30 min  followed by addition of 
piperidine (110 μL, 1.1 mmol) and 30 min stirring. Solvent and excess reagents 
were then removed under high vacuum and crude product purified by HPLC on 
the C4 column to afford pure 5 (Figure 2.2). C135H192N27O29
+. Exact mass 
calculated 2655.44, found (ESI+) 1328.3 (M + H)2+, 885.9 (M + 2 H)3+, 664.6 (M 
+ 3 H)4+, 531.9 (M + 4 H)5+. 
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Figure 2.3 LC/MS analysis of proteasome substrate from figure 2.2. (a) LC-MS of the 
protease substrate before (black) and after photolysis (blue). ESI+ MS of the primary peaks in a) PBS 
1X (100 μL) containing 5 (4 μM), DTT (5 mM was photolyzed at 360 nm for 2 min. Sample was run 
on the C4 column. Absorbance was monitored at 550 nm. Photolyzed product of 5 (compound 6, 
peak 2): C104H140N25O24
+
, calculated M+ 2123.0, found ESI+ 1062.1 (M + H)2+, 708.3 (M + 2 H)3+, 
531.5 (M + 3 H)4+, 425.4 (M +4 H)5+. Reprinted with permission from publisher.
[70]
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Fluorescence assays. Fluorescence assays were monitored using a PTI 
Technologies QuantMaster-40 equipped with cooled PMT housing. The data was 
collected using FelixGX Software. 
 
Bench photolysis. Photolysis experiments on the caged cassette or the 
protease substrate were performed using in PBS [sodium phosphate (8.06 mM), 
potassium phosphate (1.94 mM), KCl (2.7 mM) and NaCl (137 mM); pH 7.4] or in 
PBS containing 10% erythrocyte lysate, DTT (20 mM), and Halt protease and 
phosphatase inhibitors (1x). Photolysis was performed using a Zeiss Colibri 1 
LED light source (365 nm light at 100% power) for 5 min or using an Oriel Hg arc 
lamp (426 mW/cm2) for 2 min. PBS containing 1 mM MgCl2. Following 
photolysis, activity was monitored using fluorescence. 
 
Confocal microscopy. All confocal microscopy experiments were 
performed at room temperature on an Olympus FV1000 scanning confocal with 
an IX81 microscope base. Laser and region of photolysis were controlled via 
Fluoview software. Photolysis was performed using the stimulation mode with 
images collected before and after stimulation. A photolytic dwell time of 20 
μs/pixel in tornado mode was employed for the defined region of interest using 
25 frames at 405 nm and 2% power level. All imaging was performed with a 
100X at 1.9X digital zoom objective using 635 nm at 2% laser power and a dwell 
time of 12 μs/pixel. The Atto-633 peptide, in the absence of dye quencher, was 
used to generate a photobleaching curve. ImageJ software was employed for 
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image analyses. Final fluorescence intensity changes of Atto-633 were corrected 
for photobleaching effect by equation 2. 
 
Ft (corrected) = Ft x fo/ft      (Eq. 2.1)  
 
Where Ft are fluorescence values measured at time t, fo and ft are fluorescence 
values of bleaching curve at t = 0 and at t.  
 
 Widefield microscopy.  All widefield fluorescent microscopy imaging 
experiments were performed using an inverted Olympus IX81 microscope 
equipped with a Hamamatsu C8484 camera, a 60X oil immersion Plan S-Apo 
objective with 1.6x zoom, and a Texas Red filter cube (Semrock). Imaging was 
collected using Metamorph and processing was performed using Image J 
software. 
 
Results  
 
 Development of an efficient erythrocyte loading procedure. In order to 
exploit the ability of erythrocytes to form pores and load exogenous material, we 
compared the loading of three commonly used mechanisms. We evaluated the 
loading methods based on uniformity and % loading. Erythrocytes were loaded 
using hypotonic dialysis, hypotonic dilution, or electroporation with 5 μM TAMRA 
(λex: 550 nm λem: 580 nm). Our experiments determined (depicted in Figure 2.4, 
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Figure 2.5, and Figure 2.6) that TAMRA was loaded into nearly all of the cells 
with high efficiency. However, hypotonic dilution provided the best uniformity 
(fluorescence appears even in all cells) of loading. 
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Figure 2.4 Loading erythrocytes via hypotonic dialysis. Nearly all erythrocytes were loaded with 
TAMRA, however the loading appears highly uneven. White bar represents 10 μM. Phase contrast 
(left) Fluorescence (middle) overlay (right) 
 
Figure 2.5 Loading erythrocytes via hypotonic dilution. The loading appears highly uniform. 
White bar represents 10 μM Phase contrast (left) Fluorescence (middle) overlay (right) 
 
Figure 2.6 Loading erythrocytes via electroporation. While the cells were all loaded, the 
fluorescence appears punctate. White bar represents 10 μM Phase contrast (left) Fluorescence 
(middle) overlay (right) 
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 Loading of erythrocytes with peptides and proteins. We next sought to 
determine if erythrocytes can be loaded using hypotonic dilution with a 
fluorescently labeled peptide and a fluorescently labeled protein. Figure 2.7a 
shows a widefield image of an erythrocyte loaded with 1 μM TAMRA labeled PKA 
substrate. Figure 2.7b demonstrates erythrocytes can be loaded using hypotonic 
dilution with fluorescently labeled PKA. Furthermore, erythrocytes can be co-
loaded with TAMRA labeled PKA and a 10,000 MW OG dextran (Figure 2.8). 
The overlay of the red and green channel, shown in Figure 2.8c, shows a large 
number of cells are loaded with both the TAMRA labeled peptide and OG-
Dextran (yellow). 
 
   
Figure 2.7 Loading erythrocytes using hypotonic dilution with fluorophore labeled peptides 
and fluorophore labeled PKA. a) Erythrocytes were loaded with TAMRA-GRTGRRFSY and imaged 
by widefield microscopy left; transmitted image right; fluorescence image b) Overlay of erythrocytes 
loaded with Atto-633 labeled PKA and imaged by confocal microscopy. White bar represents 5 μM. 
Image a) reprinted with permission from the publisher
[63]
. 
 
a) b) 
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Figure 2.8 Erythrocytes loaded with 10,000 MW OG dextran and TAMRA labeled peptide. a) 
false color fluorescent confocal image of OG dextran loading into erythrocytes b) false color 
fluorescent confocal image of TAMRA labeled peptide c) overlay of both channel with transmitted 
image. Yellow represent erythrocytes that contain both the peptide and dextran. 
 
  
a) 
b) 
c) 
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Photolabile cassette in Fig. 2.9a. Having successfully loaded 
erythrocytes with exogenous material we sought to determine if UV light could 
induce photolysis of a nitrobenzyl moiety within intact erythrocytes (both in 
ghosts which are hemoglobin free and resealed erythrocytes that contain 
hemoglobin). In order to demonstrate this we utilized a quenched photolabile 
cassette in Fig. 2.9a that upon photolysis with UV-light furnishes a 45-fold 
fluorescent enhancement (Figure 2.9). Prior to loading the small molecule 
cassette in Fig. 2.9a into erythrocytes we wanted to demonstrate that photolysis 
could be carried out under microscopy conditions. To demonstrate photolysis 
under microscopy conditions we utilized a microwell plate and a 4x objective. 
Each well was loaded with 5 μM cassette and photolyzed for 20 s using UV 
pulses (100 μW/pulse). We demonstrated (shown in Figure 2.10) a 14-fold 
fluorescence increase in the microwells in the presence of 10 mM DTT (no 
fluorescence change observed in the absence of DTT). We next loaded 
erythrocytes with 5 μM cassette using hypotonic dilution and demonstrated that 
either a UV or a 405 laser can photolyze the cassette inside erythrocytes (as 
revealed by a fluorescence increase). Furthermore, as the inner filter effect 
associated with hemoglobin strongly interferes with nitrobenzyl absorbance, we 
sought to compare photolysis of the cassette loaded into erythrocytes in the 
presence (intact) and absence (ghosts) of hemoglobin. Although the cassette 
photolyzed more rapidly in the absence of hemoglobin, the final fluorescence 
changes were similar (Figure 2.11).  Finally, after 20 frames of photolysis (less 
than 1 s) a 5-fold fluorescence enhancement was observed (Figure 2.12). 
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Figure 2.9 Photolabile cassette. a) Molecular structure of photolabile cassette and b) fluorescence 
increase of photolabile cassette after photolysis using a mercury arc lamp with a 365 band pass filter. 
 
 
Figure 2.10 Widefield microscopy mediated photolysis of the quenched cassette using a 
microwell plate. a) Example of a microwell plate, b) fluorescence increase as a function of 
photolysis time using a UV laser equipped widefield microscope, and c) widefield images of a 
microwell before and after photolysis. 
 
a) b) 
a) c) 
b) 
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Figure 2.11 Photolysis of erythrocytes loaded with a photolabile cassette. a) Fluorescence 
increase of erythrocytes loaded with cassette b) fluorescence increase of erythrocytes cleared of 
hemoglobin and subsequently loaded with cassette. Photolysis was performed using a mercury arc 
lamp and fluorescence of the erythrocytes was subsequently measured using a plate reader. 
 
 
Figure 2.12 Erythrocytes loaded with cassette and imaged using confocal microscopy. After 
erythrocytes were loaded with the photolabile cassette, the resultant light-dependent fluorescence 
increase was monitored using confocal microscopy. Photolysis was performed using a UV and a 405 
nm laser. a) Quantitation of fluorescence increase after photolysis and b) an example of erythrocyte 
fluorescence before and after photolysis (white bar indicates 10 μM) 
 
  
Demonstration of biological activity in loaded erythrocytes. We next 
sought to determine if erythrocyte biological activity could be monitored within 
loaded erythrocytes. We utilized a membrane anchored peptide protease 
substrate that, upon photolysis with UV light, releases from the membrane and is 
able to be recognized and cleaved by proteases.[70] Erythrocytes were loaded 
a) b) 
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using hypotonic dilution and imaged using confocal microscopy. As depicted in 
Figure 2.13, erythrocytes display large increases in fluorescence after 
photolysis. Furthermore, in the presence of the protease inhibitor MG-132, or 
metal chelator EDTA, protease activity is inhibited, providing support that 
protease activity is responsible for the fluorescence increase (Figure 2.14). 
Figure 2.13 Confocal images of erythrocytes loaded with membrane anchored photocleavable 
protease substrate. a) Monitoring 5-Fam fluorescence (i) before, (ii) immediately after, (iii) 1.5 min 
after,  (iv) and 13 min after photolysis and b) monitoring TAMRA fluorescence (i) before, (ii) 
immediately after, (iii) 1.5 min after,  (iv) and 13 min after photolysis. Reprinted with permission from 
publisher
[70]
. 
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Figure 2.14 Fluorescence fold change of protease substrate loaded into erythrocytes. Fold 
increase of membrane anchored protease substrate in photolyzed (red), non photolyzed (blue), and 
photolyzed cells loaded with protease inhibitor cocktail (black). Arrow indicates first frame after 
photolysis. Reprinted with permission from publisher
[70]
. 
 
Discussion 
 
 Erythrocytes currently represent one of the most interesting methods of 
drug delivery.[18] Loading erythrocytes with exogenous small molecules for 
therapeutic delivery and/or loading erythrocytes with fluorescent reporters that 
can be used to monitor enzymatic activity represents a simple method to 
enhance delivery of therapeutic agents or diagnostic tools. More so, entrapping 
molecules in erythrocytes acts to prevent their interaction with the biological 
milieu and can protect the molecules from modification and clearance, thus 
expanding in vivo longevity in comparison to free-form (oral) therapeutic agent 
delivery methods. We explored three primary modes of erythrocyte loading: 
hypotonic dilution, hypotonic dialysis, and electroporation, for the development 
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and optimization of an efficient, versatile loading method. Of the three tested, 
hypotonic dialysis provided the highest ratio of fluorophore loaded to non-loaded 
cells; however, the uniformity of loading was poor. Electroporation represents an 
alternative option since every cell was loaded. However, this loading method 
elicited increased spontaneous erythrocyte membrane lysis and the loaded cargo 
appeared punctate (Figure 2.13). In contrast, hypotonic dilution provided robust 
substrate loading with comparable loading efficiency (percent of cells loaded) to 
hypotonic dialysis, as well as limited to no spontaneous erythrocyte lysis. 
Therefore, the hypotonic dilution loading method was used to determine whether 
peptides and proteins may also be loaded individually and co-loaded together. 
Indeed, our results revealed exogenous materials, specifically fluorophore 
labeled PKA, a 10,000 MW dextran, and substrates could be co-loaded into 
“carrier” erythrocytes and utilized for further investigations  
 Currently, nitrobenzyl groups represent an excellent method to temporally 
control an enzymatic reaction by blocking enzymatic processing until UV light 
mediated photolysis.[63] However, due to the large extinction coefficient of 
hemoglobin observed below 500 nm, hemoglobin content in erythrocytes may 
prevent UV light from photocleaving the nitrobenzyl group. We addressed this 
concern by loading erythrocytes containing hemoglobin and erythrocytes 
depleted of hemoglobin with a cassette (Fig 2.9a) containing fluorophore and a 
quencher linked together via 4,5 dimethoxynitrobenzyl. Upon photolysis, our 
cassette produces a greater than 45-fold fluorescent enhancement (Figure 2.9). 
After confirming photolysis of the cassette can be observed under microscopy 
51 
 
conditions (Figure 2.10) we loaded the cassette in erythrocytes and 
demonstrated photolysis using a UV-laser and a 405 laser. A fluorescence 
increase was observed in both hemoglobin and hemoglobin free erythrocytes. In 
the presence of hemoglobin, photolysis is likely to occur due to the relatively high 
power of light supplied and low cross section width of the erythrocytes.  
As loading of erythrocytes results in pore formation and possible leakage 
of proteins, we wanted to validate that enzymatic activity could be monitored. To 
demonstrate retention of enzymatic activity after loading, we loaded erythrocytes 
with a membrane anchored protease substrate. A protease peptide substrate 
containing TAMRA and 5-FAM is linked to a C18 via a 4,5 dimethoxynitrobenzyl 
group. The C18 group localizes the substrate to the membrane until 
photolysis.[70] After photolysis, the substrate dissociates from the membrane and 
the peptide is thus free to be recognized by proteases and subsequently 
degraded.[70] The degradation results in a fluorescent increase as the TAMRA 
and FAM fluorophores are separated. The protease substrate was loaded into 
erythrocytes and photolyzed using confocal microscopy. The observed 
fluorescent increase and subsequent inhibition with proteases inhibitors 
demonstrates that loaded erythrocytes retain enzymatic activity. 
 In summary, we demonstrated that erythrocytes can be loaded using 
hypotonic dilution with small molecules (such as TAMRA), peptides, and a 
quenched photolabile cassette as well as a 10,000 MW dextran that mimics 
protein size. Furthermore, we showed loaded erythrocytes retain enzymatic 
activity, as determined by our protease activity assay. Our work suggests 
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erythrocytes loaded in such a manner can be used to monitor intracellular activity 
of not only exogenously loaded enzymes, but also other endogenous erythrocyte 
enzymes. Our loading method and ability to temporally initiate enzymatic activity 
may prove a beneficial method to further elucidate the role of other endogenous 
erythrocyte enzymes and with the potential to be used as a diagnostic assay 
where aberrant erythrocyte enzymatic activity occurs. 
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CHAPTER 3: Monitoring Endogenous Erythrocyte PKA Activity 
 
 Overview 
 
 We demonstrate, utilizing a recently developed assay and the loading 
method developed in Chapter 2, that erythrocyte PKA activity can be monitored 
in real time with a far-red fluorophore labeled peptide substrate (Ex. 635 nm Em. 
655 nm). We opted to use a long wavelength fluorophore as the sensor as 
studying the real time activity of kinases in tissue is challenging in large part due 
to the narrow optical window. Hemoglobin is responsible for a majority of this 
interference, blocking visualization below 600 nm.  As such, the strong inner filter 
effect interferes with commercially available assays that utilize wavelengths 
shorter than 600 nm.  Using our developed peptide substrate we showed that 
erythrocyte PKA is inhibited by PKA inhibitors H89 and KT5720 in lysates. We 
extended this assay to temporally monitor PKA activity inside erythrocytes using 
confocal microscopy. Temporal control was achieved using a photolabile small 
molecule (nitrobenzyl) covalently attached to the substrate serine residue. The 
reaction is subsequently initiated by light.  
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Introduction 
 
 Serine/Threonine (S/T) kinases are a group of tightly regulated proteins 
that play critical roles in many different cellular signaling cascades. Upon binding 
to specific peptide motifs, S/T kinases catalyze the transfer of the γ- phosphoryl 
group of ATP to the hydroxyl group of a serine or threonine. This post-translation 
modification impacts a myriad of cellular behaviors ranging from apoptosis to 
motility and proliferation.[71] As S/T kinases are so vital to cellular behavior, it is 
not surprising that aberrant kinase activity is observed in many different 
diseases.[72] PKA is an example of a S/T kinase that is tightly regulated. PKA is a 
tetramer containing two regulator subunits and two catalytic subunits. Upon 
binding of cAMP to PKA holoenzyme, the regulatory subunits undergo a 
conformational change disrupting the protein-protein interface,[73] causing release 
of the catalytic subunit. This disruption allows for phosphorylation of PKA 
recognition motifs. PKA is a critical S/T kinase that is found in nearly all 
mammalian cells including erythrocytes. Indeed, even in erythrocytes, aberrant 
PKA activity has been linked to several diseases including; sickle cell disease, 
erythrocyte aging, and P. falciparum (malaria) invasion and infection.[1, 74, 75] 
Interestingly, H89, a PKA inhibitor, has been shown to be a potent inhibitor of 
malarial reproduction.[76] Although H89 is not specific to P. falciparum PKA 
(PfPKA), this suggests the importance of studying the role PKA plays in P. 
falciparum as a means to develop new therapeutic strategies.[77] Furthermore, 
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monitoring erythrocyte PKA activity could provide a diagnostic for the previously 
mentioned diseases or conditions where aberrant PKA activity is found. 
Although the value of studying S/T kinases cannot be overstated, the tools 
available to monitor the activities of S/T kinases in a biological system in a 
temporal manner are rare. Furthermore, current biochemical methods do not 
allow for the monitoring of real time endogenous kinase activity in erythrocytes. 
Developing a temporally controlled molecular reporter to monitor protein kinase 
activity in a cellular environment is challenging as many aspects must be 
considered including physiological conditions (high salt and other proteins), 
establishing a time zero, and proteolysis.  Many current probes used to study 
protein kinase activity rely on fluorescent proteins, FRET mechanisms, or 
fluorophore labeled peptide substrates to produce a fluorescent response. 
However, many of these substrates cannot be used to study activity in real time 
because they produce minimal fluorescent changes, often times as low as 
10%.[78, 79] Furthermore, probes that use fluorescent proteins and require 
transfection of plasmids to study activity cannot be used in cells that do not 
contain replicative machinery such as erythrocytes.[79] Although many kinase 
reporters are limited to minimal fluorescent changes, protease reporters do not 
suffer from this flaw and often produce dramatic fold changes, enabling real time 
activity monitoring.[70, 80-82] The ability of a protease to cleave a unimolecular 
substrate to form a bimolecular species allows for dramatic fold changes to be 
observed as fluorescent quenching can be relieved or, through cleavage, 
reporters are transformed from a non-fluorescent to a highly fluorescent state. 
56 
 
The comprehensive tool kit available to monitor protease activity has allowed for 
successful monitoring in animal models, a feat that has not been replicated to the 
same degree with kinases.[83-85] We have sought to address this limitation by 
constructing (1) temporally controlled substrates that (2) contain far-red 
fluorophores, thereby furnishing the means to monitor protein kinase activity in 
cell-based systems. 
To address the need for monitoring kinase activity in real time, we report 
the improvement of a system developed in the Lawrence lab to monitor 
endogenous PKA activity in a light dependent manner using far-red fluorophores. 
Our system utilizes a peptide substrate labeled with various different red to far-
red fluorophores (492 nm to 670 nm) and a paired small molecule quencher to 
produce dramatic fluorescent responses upon substrate phosphorylation by PKA.   
The kinase assay currently reported by our group relies on a three 
component system containing peptide, quencher, and a protein based 
recognition binding motif.[78] In this system, the quencher interacts with the 
peptide in the unphosphorylated state.  After phosphorylation the peptide is then 
recognized by the binding motif and the quencher is no longer able to interact 
with the fluorophore giving raise to dramatic fold changes.[78] The improvements 
we have made to this system are four fold. 1) We have eliminated the need for 
the binding protein, thereby reducing our assay to a two component system. 2) 
By attaching our peptide sequence to multiple different far-red fluorophores we 
have increased the utility of our assay allowing for substrates to be tuned to 
desired wavelengths making our assay compatible with samples that contain 
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high concentrations of hemoglobin or melanin such as erythrocytes or tissue. 3) 
We have identified quenchers that are able to significantly reduce fluorescence in 
biologically relevant solutions at equal molar ratios indicating tight binding. 4) We 
have established temporal control by modifying the serine in the peptide with a 
dimethoxynitrobenzyl moiety which prevents phosphorylation until the peptide is 
exposed to UV light.[86] A schematic representation of the kinase assay is shown 
in Figure 3.1. 
 
 
Figure 3.1 Schematic diagram of erythrocyte kinase activity. In the absence of light PKA is 
unable to phosphorylate the modified serine. After light stimulation the nitrobenzyl group is removed. 
In the absence of ATP and/or PKA the negatively charged quencher binds tightly to the peptide 
substrate. After phosphorylation the net charge on the peptide is reduced, resulting in quencher 
release and an increase in fluorescence. 
 
Materials and Methods 
 
Commercial Sources of Chemicals and Erythrocytes Unless otherwise 
stated, general reagents and solvents were purchased from Fisher or Sigma-
Aldrich. O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HCTU), 5-carboxyfluorescein (5-Fam), 5-
carboxytetramethylrhodamine (TAMRA), Fmoc protected amino acids, and 
NovaSyn TGR resin were purchased from Chempep, Inc (Wellington, FL) and 
NovaBiochem. Fmoc-8-aminooctanoic acid (Fmoc-Aoc-OH) was purchased from 
Advanced Chemtech (Louisville, KY). All fluorophores, other than Cy3 and Cy5, 
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were purchased from Sigma-Aldrich as either the free-carboxylic acid or as the 
NHS ester pre-activated form. Cy3 and C5 carboxylic acids were purchased from 
Lumiprobe. All reagents for the synthesis of the 4,5-dimethoxy-2-nitrobenzyl 
ether of FmocSer [Fmoc-Ser(DMNB)-OH] were purchased from Sigma-Aldrich. 
PKA inhibitors H89 and KT5720 were purchased from Sigma-Aldrich and 
Calbiochem (EMD) respectively.  Peripheral red blood cells were purchased from 
AllCells. 8-(4-chlorophenylthio) adenosine-3′,5′-cyclic monophosphorothioate 
(CPT-cAMP), ATP, and cAMP were purchased from Sigma-Aldrich. Halt 
Protease and Phosphotase inhibitors were obtained from Thermo Scientific. 
PKA, and IgG antibodies as well as secondary goat anti-rabbit antibodies were 
obtained from Abcam. GAPDH antibody was purchased from Sigma-Aldrich. 
 
Synthesis (all  compounds were synthesized by Luong T. Nguyen or Finith 
Jernigan. Syntheses are reported here for clarity and in Oien et. al.) 
 
Synthesis of fluorophore-labeled peptides. Peptides were synthesized 
using solid phase peptide synthesis. Synthesis was performed on a Prelude 
automatic peptide synthesizer from Protein Technology using Fmoc protected 
amino acids (amino acids 3 eq, HCTU 2.95 eq, DIPEA 10 eq in DMF, double 
coupling in 20 and 40 min). The 4,5-dimethoxy-2-nitrobenzyl (DMNB) modified 
Ser residue was double-coupled to resin as follows: Fmoc-Ser(DMNB)-OH (3.2 
eq.), HCTU (3 eq.), DIPEA (10 eq.) for 30 min and then Fmoc-Ser(DMNB)-OH 
(1.5 eq.), HCTU (1.5 eq.), DIPEA (10 eq.) for 40 min. Fmoc deprotection was 
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performed using 25% piperidine in DMF (3 times, 10 min each). Pre-activated 
fluorophores were coupled to peptides on resin for 4 h using 1 eq. of the pre-
activated fluorophore, 10 eq. DIPEA, and an excess amount of peptide. 
Fluorophores with a free carboxylic acid moiety were coupled to the peptides on 
resin for 4 h using 1 eq. of the fluorophore, 1.1 eq. of HCTU, 10 eq. DIPEA, and 
an excess amount peptide. 5-Fam was coupled to peptides on resin using 1.5 eq. 
of 5-Fam, 1.7 eq. of diisopropylcarbodiimide, and 10 eq. of HOBt in DMF for 2 h 
followed by 30 min treatment with 25% piperidine in DMF (2 times). Labeled 
peptides were cleaved with trifluoroacetic acid (TFA):H2O:triisopropylsilane in a 
ratio of 95:2.5:2.5, and purified by HPLC using H2O: CH3CN with 0.1 % TFA. 
 
Syntheses of Fmoc-Ser(DMNB)-OH 
 
Fmoc-L-serine allyl ester. DI Water (150 mL) containing N-α-Fmoc-L-
serine (10.22 g, 31.2 mmol) and NaHCO3 (14.36 g, 31.8 mmol) were combined 
with CH2Cl2 (60 mL) containing tricaprylmethylammonium chloride (~11 g) and 
allyl bromide (16 mL, 184.89 mmol), and the suspension was vigorously stirred at 
room temperature for 24 h. Water (300 mL) was added to the reaction mixture, 
and the suspension was extracted with CH2Cl2 (3 x 200). The combined organics 
were dried (Na2SO4) and the solvent was removed under reduced pressure. The 
crude residue was purified by silica flash chromatography (65:35 hexanes:ethyl 
acetate) to yield Fmoc-L-serine allyl ester as a white solid: 1H NMR (400 MHz, 
CDCl3) δ = 7.77 (d, J = 7.3 Hz, 2 H), 7.62 (br.d., J = 4.6 Hz, 2 H), 7.41 (t, J = 7.5 
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Hz, 2 H), 7.32 (t, J = 7.5 Hz, 2 H), 5.92 (tdd, J = 5.6, 11.0, 16.9 Hz, 1 H), 5.84 (d, 
J = 7.8 Hz, 1 H), 5.35 (d, J = 17.1 Hz, 1 H), 5.27 (dd, J = 1.1, 10.4 Hz, 1 H), 4.69 
(d, J = 5.4 Hz, 2 H), 4.53 - 4.46 (m, 1 H), 4.46 - 4.37 (m, 2 H), 4.23 (t, J = 7.0 Hz, 
1 H), 4.04 (dd, J = 3.1, 11.1 Hz, 1 H), 3.94 (dd, J = 2.9, 11.2 Hz, 1 H), 2.37 (br. 
s., 1 H). Exact mass calculated for C21H21NO5 367.14; found (ESI+) 368.1 (M + 
H)+, 390.1 (M + Na)+. 
4,5-dimethoxy-2-nitrobenzyl trichloroacetimidate. To anhydrous 
CH2Cl2; 4,5-dimethoxy-2-nitrobenzyl alcohol (8.97 g, 42.08 mmol) and anhydrous 
K2CO3 (14.2 g, 102.74 mmol) were added and stirred (120 mL) under N2 
atmosphere. To the above mixture, trichloroacetonitrile (10 mL, 99.73 mmol) and 
anhydrous triethylamine (6 mL, 43.01 mmol) were added and the reaction 
mixture stirred at room temperature for 24 h. CH2Cl2 (300 mL) was added to the 
reaction mixture. The organic layer was collected and washed with 0.5 N HCl 
followed by solvent removal. The dried crude residue was purified by silica flash 
chromatography (75:25 hexanes:ethyl acetate) to give 4,5-dimethoxy-2-
nitrobenzyl trichloroacetimidate: 1H NMR (400 MHz, CDCl3) δ = 8.51 (s, 1 H), 
7.75 (s, 1 H), 7.23 (s, 1 H), 5.78 (s, 2 H), 3.97 (s, 3 H), 3.96 (s, 3 H). Exact mass 
calculated for C11H11Cl3N2O5 355.97; found (ESI+) 374.9 (M + H3O)+. 
N-(9-fluorenylmethyloxycarbonyl)-o-(4,5-dimethoxy-2-nitrobenzyl)-L-
serine allyl ester. Fmoc-serine allyl ester 4 (1.74 g, 4.75 mmol) and the 4,5-
dimethoxy-2-nitrobenzyl trichloroacetimidate (3.22 g, 9.04 mmol) were dissolved 
in CH2Cl2 (40 mL) and mixed under nitrogen atmosphere at room temperature. 
To the above solution was slowly added a solution of triflic acid in CH2Cl2 (75 µL 
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triflic acid in 5 mL CH2Cl2). The reaction mixture was stirred at room temperature 
for 30 min after the completion of the triflic acid addition. N,N-
diisopropylethylamine (DIPEA, 150 μL) in CH2Cl2 (10 mL) and silica gel were 
added to the reaction mixture and then concentrated under reduced pressure. 
The crude residue, adsorbed on silica, was purified by silica flash 
chromatography (67:33 hexanes:ethyl acetate) to afford N-(9-
fluorenylmethyloxycarbonyl)-o-(4,5-dimethoxy-2-nitrobenzyl)-L-serine allyl ester: 
1H NMR (400 MHz, CDCl3) δ= 7.77 (d, J = 7.5 Hz, 2 H), 7.72 (s, 1 H), 7.61 (t, J = 
6.7 Hz, 2 H), 7.41 (t, J = 7.3 Hz, 2 H), 7.31 (t, J = 6.6 Hz, 2 H), 7.18 (s, 1 H), 5.97 
- 5.82 (m, 1 H), 5.71 (d, J = 8.4 Hz, 1 H), 5.33 (d, J = 17.1 Hz, 1 H), 5.23 (d, J = 
10.4 Hz, 1 H), 4.98, 4.92 (ABq, JAB = 15.4 Hz, 2 H), 4.71 (d, J = 5.1 Hz, 2 H), 
4.68 - 4.62 (m, 1 H), 4.48, 4.39 (ABXqd, JAB = 10.5 Hz, JAX = 6.8 Hz, JBX = 6.9 
Hz, 2 H), 4.24 (t, J = 7.1 Hz, 1 H), 4.18 - 4.04 (m, 2 H), 3.96 (s, 3 H), 3.95 (s, 3 
H), 3.94 - 3.89 (m, 1 H). Exact mass calculated for C30H30N2O9 562.20; found 
(ESI+) 563.2 (M + H)+, 585.2 (M + Na)+. 
N-(9-Fluorenylmethyloxycarbonyl)-O-(4,5-dimethoxy-2-nitrobenzyl)-L-
serine. The DMNB modified serine allyl ester 6 (1.00 g, 1.78 mmol) was 
dissolved in CHCl3 (40 mL) containing acetic acid (21 mL) and N-
methylmorpholine (3 mL). To the above solution was added Pd(Ph3P)4 (0.97 g, 
0.84 mmol). The reaction mixture was stirred for 4 h at room temperature and 
neutralized by the addition of 0.1 N HCl until pH 4 and then the suspension was 
extracted with CH2Cl2 (twice) and ethyl acetate (three times). The organic 
extracts was dried (Na2SO4), and concentrated under reduced pressure. The 
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crude residue was purified by silica flash chromatography (CH2Cl2 and then 48:2 
CH2Cl2:CH3OH) to yield N-(9-Fluorenylmethyloxycarbonyl)-O-(4,5-dimethoxy-2-
nitrobenzyl)-L-serine: 1H NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.6 Hz, 2 H), 
7.66 (s, 1 H), 7.60 (t, J = 5.9 Hz, 2 H), 7.40 (t, J = 7.5 Hz, 2 H), 7.31 (dt, J = 1.2, 
6.4 Hz, 2 H), 7.10 (s, 1 H), 5.69 (d, J = 8.3 Hz, 1 H), 4.97, 4.87 (ABq, JAB = 
15.29, 2 H), 4.68 (br.s., 1 H), 4.53 - 4.37 (m, 2 H), 4.23 (t, J = 6.7 Hz, 1 H), 4.12 
(d, J = 9.2 Hz, 1 H), 3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 - 3.83 (m, 1 H). 1H NMR 
(400 MHz , acetone-d6) = 7.86 (d, J = 7.6 Hz, 2 H), 7.73 (dd, J = 3.8, 7.4 Hz, 2 
H), 7.70 (s, 1 H), 7.44 - 7.37 (m, 3 H), 7.35 - 7.28 (m, 2 H), 4.98, 4.92 (ABq, JAB 
= 15.7 Hz, 2 H), 4.58 (t, J = 4.5 Hz, 1 H), 4.41 - 4.29 (m, 2 H), 4.28 - 4.21 (m, 1 
H), 4.09 (dd, J = 4.9, 9.6 Hz, 1 H), 3.98 - 3.94 (m, 1 H), 3.93 (d, 6 H). Exact mass 
calculated for C27H26N2O9 522.16; found (ESI+) 523.2 (M + H)+, 545.1 (M + 
Na)+. 
 
Peptide purification. A Waters HPLC instrument was used to purify all 
peptides. Flash chromatography purification was performed using an Isolera One 
instrument (Biotage) equipped with a silica or C18 column (Biotage). Peptides 
were either purified using C18 flash chromatography or C18 HPLC (Apollo C18, 
5 μm, 250 x 22 mm column). LC-MS analytical characterizations were run on an 
Agilent instrument equipped with UV-VIS and quadrupole mass detectors using 
either a Viva C4 column (5 μm, 50 x 2.1 mm) from Restek or a Prevail C18 
column (3 μm, 50 x 2.1 mm) from Alltech Associates, Inc. All LC-MS experiments 
were conducted using H2O-CH3CN solvents with 0.1% formic acid.  
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Absorbance measurements. Absorbance measurements were 
performed using a Perkin Elmer Lambda 25 UV/Vis spectrophotometer. Data 
was collected using UV WinLab. To collect erythrocyte lysate absorbance, 
washed erythrocytes were lysed using mechanical shearing. The lysed 
erythrocytes were then centrifuged at 10,000 rpm for 3 min and the supernatant 
collected. The supernatant was then diluted 100-fold and the absorbance 
measurements collected between 450 - 700 nm. The absorbance spectra were 
also collected for 5-Fam, Atto620, TAMRA, Red681, and Atto633 (Fluorophore-
Aoc-GRTGRRFSY) peptides at 2 μM. The absorbance maxima between 475 and 
700 for each sample were normalized to 1. 
 
Fluorescence measurements. 200 μL 96 well plate fluorescence assays 
were performed using a Molecular Devices SpectraMax Gemini EM Dual-
Scanning Microplate Spectrofluorometer. Data was collected using SoftMax Pro 
Software. Alternatively, protein kinase activities were monitored using a PTI 
Technologies QuantMaster-40 equipped with cooled PMT housing. The data was 
collected using FelixGX Software. Sensor monitoring studies were performed 
using a plate reader in a 96 well format (200 µL/well) in Tris-HCl (25 mM, pH 
7.5), MgCl2 (1 mM), PKA (10 nM), peptide (1 μM) and quencher concentrations 
mentioned in the figures. Reactions were initiated with the addition of ATP (final 
concentration of 1 mM). Excitation and emission wavelengths are reported in 
Table 1.1. 
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Screening of the dye library. 200 µL kinase buffer containing Tris-HCl 
(25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM) and fluorophore-peptide (2.5 or 5 
μM) were added to wells of a 96-well plate. Dyes (Table 3.1, concentration 
ranging from 5 μM to 60 μM) were then added to each well and the initial 
fluorescence recorded. Phosphorylation was initiated by the addition of PKA (10 
nM) into each well and fluorescence was monitored over time. Dyes that 
produced a fluorescent increase upon the PKA addition were selected for further 
confirmation by replication in the plate reader or spectrofluorometer. 
Phosphorylation products were confirmed by LC-MS. 
 
Comparison of kinase reporter assay using various salt 
concentrations. Fluorophore-labeled peptides were added to 200 μL of either 
“no salt” buffer containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM) 
or “with salt” buffer containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 
mM), and NaCl (150 mM) followed by incubation (5 min at 30 °C). Various 
quenchers were then added to the solutions followed by incubation (5 min at 
30 °C) and the addition of PKA (to 10 nM) to initiate phosphorylation. 
Fluorescence fold change = Ff/Fq, and fluorescent quenching = 100*(Fi-Fq)/Fi, 
where Fi, Fq, Ff are the fluorescence of the reaction mixture in the absence of 
quencher, in the presence of quencher, and after the phosphorylation reaction is 
completed, respectively.  
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Job plots. Various ratios of peptide (TAMRA-Aoc-GRTGRRFSY) and 
quencher dye (Acid Blue 80 1 or Evans Blue 2) at a fix total concentration of 
peptide and quencher dye (5 μM) were added to 200 μL kinase buffer containing 
Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM), and NaCl (150 mM). 
Mixtures were then incubated at room temperature for 10 min before the 
absorbance measurements were taken.  
 
Determination of dye concentrations that generate a 50% loss in 
fluorescence (EQ50) of fluorophore-labeled peptides. The contribution to 
signal loss due to the inner filter effect of the dye was subtracted during the 
EQ50 determination. In the rear chamber of a two chamber cuvette (Precision 
Cells, LT125ES10), peptide (1 μM) was added to PBS buffer [sodium phosphate 
(8.06 mM), potassium phosphate (1.94 mM), KCl (2.7 mM), and NaCl (137 mM); 
pH 7.4] and in the front chamber varying concentrations of either Acid Blue 80 1 
or Evans Blue 2 (0.1 to 32 μM) was added to PBS buffer. The reduction in 
fluorescence was calculated as a percent loss in initial fluorescence from the 
control where [Dye] = 0 µM. This curve was applied to respective samples. 
EQ50’s were determined by adding peptide (1 μM) and varying concentrations of 
quencher (0.1 to 32 μM) in PBS buffer and after removing the contribution due to 
the inner filter effect. EQ50’s were determined by fitting the data to Equation 3.1. 
 
% Fluorescent Quench = 
Bmax  [Dye 
EQ50 + [Dye 
     (Eq. 3.1) 
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Where Bmax is the maximum amount of fluorescent quenching observed 
(100%), [Dye] is the quencher dye concentration, and EQ50 is the concentration 
at which 50% quenching is observed.  
 
IC50 determinations of PKA inhibitors KT5720 and H89. Assays were 
set up with 200 µL of PBS buffer containing, Atto633-Aoc-GRTGRRFSY (1 µM) 
Evans Blue 2 (2 µM) was allowed to equilibrate at 25 °C in a spectrofluorometer. 
The PKA-catalyzed reaction was initiated by adding a stock solution of ATP and 
cAMP (100 mM each, pH 7.4) to give a final concentration of 500 µM of ATP and 
of cAMP. Relative initial rates were determined (relative to no inhibitor control) in 
triplicate in the presence of H89 or KT5720 (50 nM to 5 μM). Relative rates were 
plotted vs H89 or KT5720 concentration and the IC50 value determined using 
GraphPad Prism 5 software. 
  
Erythrocyte lysates: 200 µL of PBS containing lysed erythrocytes (10%), 
Atto633-Aoc-GRTGRRFSY (1 µM), Evans Blue 2 (2 µM), and Halt protease and 
phosphatase inhibitor cocktail (1x) was allowed to equilibrate at 25 °C in a 
spectrofluorometer. The PKA-catalyzed reaction was initiated by adding a stock 
solution of ATP and cAMP (100 mM each, pH 7.4) to give a final concentration of 
500 µM of ATP and of cAMP. Relative initial rates were determined in triplicate in 
the presence of H89 or KT5720 (50 nM to 5 μM). Relative rates were plotted vs 
H89 or KT5720 concentration and the IC50 value determined using GraphPad 
Prism 5 software.  
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PKA activity in erythrocyte lysates. Peripheral erythrocytes were 
washed three times in PBS by centrifuging at 1400 g for 10 min. After each 
centrifugation the supernatant was removed by aspiration and replaced with PBS 
buffer. After the final wash, erythrocytes were suspended to 50% hematocrit 
levels and lysed in the presence of DTT (20 mM) with mechanical shearing. The 
lysed erythrocytes were then centrifuged at 10,000 rpm for 3 min and the 
subsequent supernatant was used for assay measurements. 
Kinase assays were performed in a 200 μL cuvette using a PTI 
spectrofluorometer. Solutions contained PBS buffer with fluorophore labeled 
peptide (1 μM), MgCl2 (5 mM), Halt protease and phosphatase inhibitor (1x), and 
lysed erythrocytes (10%). Reactions were initiated with the addition of cAMP and 
ATP to a final concentration of 1 mM each.  
 
Fluorescence signal loss study due to erythrocyte lysates. A two-
chambered cuvette (Precision Cells, LT125ES10) was filled with PBS or PBS 
and 10% lysate in one chamber and PBS containing 5-Fam, TAMRA, or Atto633 
Aoc-GRTGRRFSY (1 μM) in the second chamber. The fluorescence spectrum 
was measured for each peptide using their corresponding maximum excitation 
and emission wavelengths. 
PKA clearing and western blot analysis. Erythrocyte PKA clearing was 
performed using erythrocyte lysates (see above). Erythrocyte lysates (500 μL) 
were incubated with antibody (10 μL) (anti-PKA C subunit or anti-rabbit IgG) at 
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4 °C overnight. Protein A agarose was then added to the samples and incubated 
at 4 °C for 4 h. The samples were then placed in Bio-Rad Micro Bio-Spin 
chromatography Columns and eluted by centrifuging at 1000 g for 4 min. The 
eluent was then collected and PKA activity was monitored using TAMRA-Aoc-
GRTGRRFSY via the aforementioned method and relative PKA levels were 
quantitated via western blot. 
PKA cleared, IgG control, and non-cleared erythrocyte lysate samples 
were normalized to 550 nm. 20 μL of normalized lysate was loaded onto 4–12% 
bis-tris polyacrylamide gels, separated by electrophoresis, and electroblotted 
onto PVDF membranes. The membranes were then blocked in PBS with tween 
20 and 0.5% nonfat dry milk followed by incubation with the appropriate primary 
antibody (PKA C subunit 1:1000,) at 4 °C overnight. The membranes were then 
washed 3 times with Tween-20 (0.1%) in PBS followed by incubation with a goat 
anti-rabbit secondary antibody (1:2000) for 2 h at RT. Subsequent washes with 
Tween-20 (0.1%) in PBS (three times), PBS (three times), and 0.5% NaCl (three 
times) were performed prior to detection with GE Amersham ECL Western 
blotting detection reagent. After image acquisition the membrane was stripped 
using Restore™ PLUS Western Blot Stripping Buffer (Thermo) and subsequently 
blotted with rabbit Anti-GAPDH via the aforementioned protocol. Images were 
analyzed using Image J; PKA levels were quantitated relative to GAPDH levels. 
Photoconversion of inactive sensor (DMNB protected Att633-Aoc-
GRTGRFSY) to active sensor for erythrocyte lysate studies. Photolysis 
experiments on Atto633-Aoc-GRTGRRFS(DMNB)Y were performed in PBS or in 
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PBS buffer containing 10% erythrocyte lysate, DTT (20 mM), and Halt protease 
and phosphatase inhibitors (1x). Photolysis was performed using a Zeiss Colibri 
1 LED light source (365 nm light at 100% power) for 5 min or using a mercury arc 
lamp for 2 min. PBS containing Atto633-Aoc-GRTGRRFSY (1 μM), Evans Blue 
(2 μM), and PKA (10 nM) was photolyzed. Following photolysis, activity was 
monitored using fluorescence by the addition of ATP (1 mM) to initiate the 
phosphorylation. 
 
Erythrocyte integrity assessment in the presence of dye 
fluorescence quenchers and UV/405 nm light. Erythrocytes were washed 
three times in PBS. Packed erythrocytes were then diluted to 10% in PBS. 
Erythrocytes were then exposed to dye fluorescent quencher (Acid Blue 80 [1] or 
30 μM Evans Blue [2]) and 405 nm or UV light for 5 min. Loss of erythrocyte 
integrity as assessed by lysis was determined by spinning the treated erythrocyte 
solution at 2000 g for 5 min and monitoring the supernatant absorbance at 414 
nm. Experimental results were compared to controls: (1) no dye quencher, (2) in 
the dark, and (3) sonication for 30 s (resulting in 100%).  
 
 
Loading kinase assay into erythrocytes. Erythrocytes were loaded with 
peptide and dye quencher via a hypotonic dilution method. Whole peripheral 
erythrocytes were washed three times in PBS. Erythrocytes were then stored 
overnight at 4 °C to deplete any remaining ATP. Washed erythrocytes (50 μL, 
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50%) were added to a solution containing Atto633-Aoc-GRTGRRFS(DNMB)Y (1 
μM), Evans Blue (2) (2 μM), ATP (5 mM), CPT-cAMP (1 mM), Tris-HCl (10 mM, 
pH 7.5), and Halt protease and phosphatase inhibitor cocktail (1x) to a final 
volume of 500 μL. The solution was incubated on ice (10 min) and turned a 
transparent red. 52.7 μL of 10x buffer [KCl (1.22 M), MgCl2 (180 mM), glucose 
(100 mM), and Tris-HCl (100 mM, pH 7.5)] was then added to the erythrocyte 
solution, which changed from transparent to opaque. At this point erythrocytes 
were allowed to recover at 4 °C for 30 min. 5 μL of DTT (1 M) and 5 μL of Evans 
Blue (2) (400 μM) were then added to the erythrocyte solution. Several studies 
have demonstrated that, upon resealing, erythrocytes are unable to completely 
reseal the membrane. To prevent loss of smaller molecules (ATP, cAMP, or 
quencher) the erythrocytes were not washed.[11, 87, 88] For microscopy 
experiments, 7 μL of the final erythrocyte solution was placed between two cover 
slips. Erythrocytes added to the cover slips were allowed to rest for 10 min, and 
subsequently imaged using confocal microscopy. For flow cytometry 
experiments, the same solution was washed once in PBS buffer and re-
suspended in PBS containing Evan’s Blue (2) (10 μM). The erythrocyte solution 
was then filtered through Partec CellTrics® filters and analyzed by flow 
cytometry. 
 
Flow cytometry. Erythrocytes loaded with (1) Atto633-Aoc-
GRTGRRF(DMNB)SY (1 µM) alone, (2) Atto633-Aoc-GRTGRRF(DMNB)SY (1 
µM) and Evans Blue (2) (2 µM), and (3) neither were analyzed using flow 
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cytometry. Flow cytometry was performed on a BD LSR II flow cytometer in UNC 
Flow Cytometer Core Facility in the Department of Microbiology and 
Immunology. 
 
Confocal microscopy. All microscopy experiments were performed at 
room temperature on an Olympus FV1000 scanning confocal with an IX81 
microscope base. Laser and region of photolysis were controlled via Fluoview 
software. Photolysis was performed using the stimulation mode with images 
collected before and after stimulation. A photolytic dwell time of 20 μs/pixel in 
tornado mode was employed for the defined region of interest using 25 frames 
with the 405 nm laser at 2% power level. All imaging was performed with a 100X 
objective using a 635 laser nm at 2% power. The Atto-633 peptide, in the 
absence of dye quencher, was used to generate a photobleaching curve. ImageJ 
software was employed for image analyses. Final fluorescence intensity changes 
of Atto-633 were corrected for photobleaching effect by equation 3.2.  
 
Ft (corrected) = Ft x fo/ft       (Eq. 3.2) 
 
Where Ft are fluorescence values measured at time t, fo and ft are fluorescence 
values of bleaching curve at t = 0 and at t. 
 
Western blot analysis of CPT-cAMP stimulated erythrocytes. Western 
blot analysis was performed using erythrocyte lysates (see above) that had been 
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stimulated with 1 mM CPT-cAMP, DMSO (Control), or 1 mM CPT-cAMP and 10 
μM H89. PKA stimulated erythrocyte lysate samples were normalized to 550 nm. 
20 μL of normalized lysate was loaded onto 4–12% bis-Tris polyacrylamide gels, 
separated by electrophoresis, and electroblotted onto PVDF membranes. The 
membranes were then blocked in PBS + tween containing 0.5% nonfat dry milk 
followed by incubation with the appropriate primary antibody (PAN p-PKA-
substrate subunit 1:1000,) at 4 °C overnight. The membranes were then washed 
3 times with Tween-20 (0.1%) in PBS. followed by incubation with a goat anti-
rabbit secondary antibody (1:2000) for 2 h at RT. Subsequent washes with 
Tween-20 (0.1%) in PBS (three times), PBS (three times), and 0.5% NaCl (three 
times) were performed prior to detection with GE Amersham ECL Western 
blotting detection reagent. After image acquisition the membrane was stripped 
using Restore™ PLUS Western Blot Stripping Buffer (Thermo) and subsequently 
blotted with rabbit Anti-GAPDH via the aforementioned protocol.  
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Results 
 
Identification of quencher-fluorophore pairs for monitoring PKA 
activity. Two peptide sequences that are phosphorylated by PKA were selected 
based on prior literature sources.[89, 90] Red to far-red fluorophores were 
appended to the N-termini of the peptides and each peptide-fluorophore 
conjugate was incubated with each of the 48 quenchers. All 18 fluorophore 
labeled peptides were screened against the 48 quenchers (Table 3.1 and 3.2). 
PKA was added to initiate the assay to screen the quencher library. Fluorophore-
quencher pairs that produced the brightest fluorescent responses are reported. 
The quenchers that were identified in the screen had similar characteristics. The 
quencher’s maximum absorbance occurs between 550 and 650 nm and the 
quenchers that produced the brightest responses are negatively charged. This 
implies that the mechanism of the fluorescence response is primarily based on a 
charge interaction between the negatively charged quencher and the positively 
charged peptide. Peptide-quencher pairs were then tested in the presence of 
salt. Our results showed (Table 3.3) that salt reduces the ability of the 
quenchers, Acid Blue 80 and Acid Blue 27, to quench fluorescence. Evans Blue 
was also tested in the presence of salt, and was identified to show larger 
increases (Table 3.4). Generally, the ability of the quencher to reduce 
fluorescence was strongly correlated with the fluorescence fold change after 
addition of PKA. We showed (Figure 3.2) that the greater the percentage of 
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fluorescent quenching, the greater the fluorescent fold change upon 
phosphorylation.  
Table 3.1 Quenchers used in PKA assay screen. Quenchers most often identified in the kinase 
screen are bolded. 
 
  
 
  
λmax (nm) <500 501-550 551-600 601-650 651-700
Dyes Disperse Yellow 3 Acid Fuchsin Acid Green 25 Acid Blue 129 Azure B bromide 
Acid Alizarin Violet N Acid Red 27 Brilliant Blue R Acid Blue 40 Methylene Blue 
Acridine Orange Basic Fuchsin Bromocresol Purple Acid Blue 80
Acridine Yellow G Eriochrome Black T Bromophenol Blue Acid Green 27
Bismark Brown Y Erythrosin Chlorazol Black E Alizarin Red
Brilliant Yellow Methyl Orange Chlorophenol Red Aniline Blue WS
Carminic Acid Nuclear Fast Red Ethyl Violet Azure A
Chrysoidine Y Ponceau S Methyl Violet Evans Blue 
Cresol Red Rose Bengal Phenol Red Malachite Green oxalate 
Ethyl Orange Phenolphthalein Naphthol Blue Black
Methylthymol Blue Safranin O Trypan Blue
N,N-dimethylnitrosoaniline Xylene Cyanol FF
Rosolic Acid
Tartrazine
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Table 3.2 Fluorescent increase of peptides associated with quenchers after addition of PKA. 
Each of the following fluorophore labeled peptides were screened against the 48 quenchers in Table 
3.1. The hits that produced the best fluorescent fold changes after reaction initiation are reported 
below with the concentration of quencher. Numbers in parenthesize represent concentrations in μM. 
Reprinted with permission from publisher.
[63]
 
 
Peptide 
(concentration μM) 
Quencher 
(concentration μM) 
Fluorescent fold change ± sd 
5-Fam-KRRRLASLAA (2.5) Acid green 27 (30) 3.70 ± 0.8 
Cy3-KRRRLASLAA (2.5) Bromophenol Blue (20) 5.05 ± 0.12 
TAMRA-KRRRLASLAA (2.5) Acid Blue 80 (15) 24.50 ± 1.4 
Atto610-KRRRLASLAA (2.5) Bromophenol Blue (35) 5.47 ± 0.15 
Atto620-KRRRLASLAA (2.5) Acid Blue 80 (7.5) 21.85 ± 0.47 
Red630-KRRRLASLAA (2.5) Bromophenol Blue (30) 3.97 ± 0.54 
Atto635-KRRRLASLAA (2.5) Bromophenol Blue (35) 4.19 ± 0.18 
Cy5-KRRRLASLAA (2.5) * Bromophenol Blue (20) 5.82 ± 0.23 
Atto655-KRRRLASLAA (2.5) Acid Blue 80 (10) 16.71 ± 0.51 
Atto680-KRRRLASLAA (2.5) Acid Blue 80 (15) 22.54 ± 2.67 
Red681-KRRRLASLAA (2.5) Acid Blue 80 (5) 13.83 ± 0.67 
NIR700-KRRRLASLAA (2.5)  Bromocresol Purple (80) 2.73 ± 0.05 
NIR730-KRRRLASLAA (2.5)  Bromocresol Purple (80) 2.59 ± 0.19 
5-Fam-Aoc-GRTGRRFSY (2.5) Acid green 27 (30) 21.19 ± 0.41 
TAMRA-Aoc-GRTGRRFSY (2.5) Acid Blue 80 (15) 100.68 ± 27.5  
Atto620-Aoc-GRTGRRFSY (2.5) Acid Blue 80 (7.5) 31.36 ± 1.04 
Red681-Aoc-GRTGRRFSY (2.5) Acid Blue 80 (5) 11.18 ± 0.57 
Atto633-Aoc-GRTGRRFSY (2.5) Acid Blue 80 (5) 30.93 ± 4.89 
 
Table 3.3 Effect of salt on the fluorescent response of PKA sensors upon phosphorylation. 
The addition of 10 nM PKA was used to initiate phosphorylation. Fold change = Ff/Fq, Fluorescent 
quenching = (Fi-Fq)/Fq, where Fi, Fq, Ff were the fluorescence of the reaction mixture in the absence 
of quencher, in the presence of quencher, and after phosphorylation reaction completed, 
respectively. Reprinted with permission from publisher.
[63]
 
 
Buffer 
condition 
Peptide (2.5 μM) Quencher 
(concentration/μM) 
Fluorescent 
quenching 
(%) 
Fold change 
after 
phosphorylation 
No salt 5Fam-Aoc-GRTGRRFSY Acid green 27 (30) 97.2 ± 0.3 18.5 ± 3.4 
With salt 5Fam-Aoc-GRTGRRFSY Acid green 27 (30) 97.0 ± 0.1 3.5 ± 0.5 
No salt TAMRA-Aoc-GRTGRRFSY Acid Blue 80 (15) 99.8 ± 0.1 103.7 ± 24.4 
With salt TAMRA-Aoc-GRTGRRFSY Acid Blue 80 (15) 99.7 ± 0.0 41.0 ± 1.2 
No salt Atto620-Aoc-GRTGRRFSY Acid Blue 80 (7.5) 99.1 ± 0.1 16.6 ± 0.8 
With salt Atto620-Aoc-GRTGRRFSY Acid Blue 80 (7.5) 98.6 ± 0.0 18.2 ± 0.1 
No salt Atto633-Aoc-GRTGRRFSY Acid Blue 80 (5) 99.4 ± 0.3 30.2 ± 9.1 
With salt Atto633-Aoc-GRTGRRFSY Acid Blue 80 (5) 98.6 ± 0.2 23.6 ± 3.0 
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Table 3.4 Effect of salt on the fluorescent response upon phosphorylation of peptides with 
Evans Blue. Either “no salt” buffer (200 μL) containing tris-HCL (25 mM, pH 7.5), MgCl2 (1 mM), 
ATP (1 mM) or “with salt” buffer (200 uL) containing tris chloride (25 mM, pH 7.5), MgCl2 (1 mM), 
ATP (1 mM), and 150 mM NaCl were added peptides followed by 5 min incubated at 30 °C. To the 
reaction mixture were then added evan blue (2.5 μM) followed by 5 minute incubation at 30 oC and 
the addition of 10 nM PKA to initiate the phosphorylation. Fold change and fluorescent quenching 
were calculated as previously described. Reprinted with permission from publisher.
[63]
 
 
Buffer 
condition 
Peptide 
(2.5 μM) 
Fluorescent 
quenching 
(%) 
Fold change 
after 
phosphorylation 
No salt 5Fam-Aoc-GRTGRRFSY 80.9 ± 1.5 2.9 ± 0.5 
With salt 5Fam-Aoc-GRTGRRFSY 62.1 ± 1.1 1.4 ± 0.0 
No salt TAMRA-Aoc-GRTGRRFSY 99.8 ± 0.0 20.6 ± 2.9 
With salt TAMRA-Aoc-GRTGRRFSY 99.8 ± 0.0 34.6 ± 14.5 
No salt Atto633.Aoc-GRTGRRFSY 98.0 ± 0.4 2.0 ± 0.3 
With salt Atto633-Aoc-GRTGRRFSY 94.6 ± 1.3 3.0 ± 0.5 
  
 
 
Figure 3.2 Fluorescent fold increase of Atto680-KRRRLASLAA (2.5 uM) due to PKA 
phosphorylation with various Acid Blue 80 concentrations. Relative fluorescent quenching = (1- 
Fi/Fo) (a), relative fluorescent recovery = (Ff-Fi)/Fo (b). Fluorescent fold change = Ff/Fi, where Fi and 
Fo were the fluorescence in the presence and absence of quencher respectively; Ff was the final 
fluorescence after the phosphorylation has completed in the presence of quencher. Reprinted with 
permission from publisher.
[63]
 
 
Quencher compatibility with erythrocytes. Quenchers Acid Blue 80 and 
Evans Blue were mixed with intact erythrocytes and tested in the presence and 
absence of UV and 405 nm light (as it is known that both UV light and 405 nm 
a) 
b) 
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light can induce photolcleavage of the nitrobenzyl-serine C-O bond). Erythrocyte 
lysis was determined by measuring hemoglobin release in the supernatant 
(Figure 3.3). Evans Blue was determined to be well tolerated and exposure of 
erythrocytes to 405 nm light had minimal impact on erythrocyte viability. 
Erythrocytes exposed to Acid Blue 80 experienced dramatic lysis. 
 
Figure 3.3 Percent erythrocyte lysis from exposure to quenchers. Evans Blue is labeled 1, and 
Acid Blue 80 is labeled 2. Reprinted with permission from publisher.
[63]
 
 
Measuring affinity for quenchers to Atto633-peptide.  To assess the 
ability of the quencher to interact with the peptide we measured the binding 
affinity. A high binding affinity is necessary as the higher the binding affinity the 
more specifically the quencher will interact with the peptide. A 1:1 binding is 
determined by a Job Plot containing a single maximum peak. As the Job Plots 
depicted in figure 3.4, each contain more than one maximum peak the relative 
affinity of quenchers Acid Blue 80 and Evans Blue toward the fluorophore labeled 
peptide was measured by calculating the concentration required to quench 50% 
of the fluorescence (EQ50). Figure 3.5 shows that Evans Blue has a greater 
apparent affinity for the peptide then Acid Blue 80. Next we increased the salt 
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concentration and demonstrated that salt decreases the affinity (Figure 3.6). 
Finally, we measured the change in apparent affinity of Evans Blue in the 
presence of lysate and determined the affinity was reduced (Figure 3.7). 
Figure 3.4 Job plot analysis of a) Acid Blue 80 and b) Evans Blue. Job plots were determined for 
both quenchers using Atto633-Aoc-GRTGRRFSY at 556 nm. Reprinted with permission from 
publisher.
[63]
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Figure 3.5 EQ50 of Acid Blue 80 (a) and Evans Blue (b) for Atto633-Aoc-GRTGRRFSY. 1 
indicates Acid Blue 80 and 2 indicates Evans Blue. Reprinted with permission from publisher.
[63]
 
 
a) 
b) 
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Figure 3.6 Effect of salt on EQ50 of Atto633-Aoc-GRTGRRFSY. Quenching of Atto633-Aoc-
GRTGRRFSY (1 μM) fluorescence as a function of Acid Blue 80 (1) at various NaCl concentrations, 
where (a) [NaCl] = 0 mM (circles, EQ50 = 0.69 ± 0.07 μM), (b) 50 mM (squares, EQ50 = 1.5 ± 0.14 
μM), (c) 100 mM (triangles, EQ50 = 1.6 ± 0.16 μM), and (d) 150 mM (inverted triangles, EQ50 = 1.9 ± 
0.2 μM). Reprinted with permission from publisher Reprinted with permission from publisher.
[63]
 
Figure 3.7 Effect of lysates on quenching of Atto633-Aoc-GRTGRRFSY. Fluorescence 
Quenching of Atto633-Aoc-GRTGRRFSY (1 μM) by Acid Blue 80 (1) (circles, EQ50 = 8.1 ± 1.7 μM) 
and Evans Blue (2) (squares, EQ50 = 0.35 ± 0.03 μM) in the presence of 10% erythrocyte lysate. 
Reprinted with permission from publisher.
[63]
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Selection of fluorophore for lysate and cellular assays. Erythrocytes 
have a strong absorbance band below 550 nm. Therefore, the fluorophores used 
to monitor PKA activity were chosen with this in mind. Atto633 and TAMRA 
labeled peptides were used to measure activity in erythrocyte lysates. We 
demonstrated (Figure 3.8) that PKA activity can be monitored in 10% hematocrit 
erythrocyte lysates using either fluorophore, but increasing the hematocrit 
completely abolished the TAMRA labeled peptide signal. Although the fold 
change is reduced for the Atto633-Aoc-GRTGRRFSY, this may be due to a 
reduction in the quencher’s interaction with the peptide, Atto633-Aoc-
GRTGRRFSY was used for future studies as the signal to noise is better. 
Figure 3.8 Fluorescence increase of Atto633-Aoc-GRTGRRFSY and TAMRA-Aoc-GRTGRRFSY 
in 10% erythrocyte lysates and in 100% erythrocyte lysates (inset) Reprinted with permission 
from publisher.
[63]
 
 
Demonstrating PKA specificity. PKA inhibitors H89 and KT5720 were 
used to demonstrate that PKA activity was specifically monitored using our 
assay. Both H89 and KT5720 inhibit PKA activity in buffer and erythrocyte 
lysates (Figure 3.9). Furthermore, kinase inhibitors not specific to PKA (all used 
TAMRA 
Atto633 
TAMRA 
Atto633 
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at 1 μM) did not inhibit activity in lysates (Figure 3.10). Gö6938 is known to be a 
potent PKC inhibitor, but has also been shown to have some ability to inhibit PKA 
(IC50 of 9 μM) which may explain the partial inhibition observed.  Lastly, 
erythrocyte lysates cleared of PKA demonstrated reduced rate of 
phosphorylation as evidenced by the reduce fluorescence signal. Furthermore, 
the reduced rate of phosphorylation correlates to the amount of PKA cleared 
(Figure 3.11). 
Figure 3.9 Inhibition of PKA activity by specific inhibitor H89 in buffer by (a) H89 and (b) 
KT5720. IC50 (H89) = 430 ± 150 nM; IC50 (KT5720) = 610 ± 250 nM. In 10% erythrocyte lysates by 
(c) H89 and (d) KT5720. 200 μL buffer containing PBS, MgCl2 (1 mM), ATP (100 μM) 10% 
erythrocyte lysates IC50 (H89) = 1.14 ± 0.17 μM; IC50 (KT5720) = 1.59 ± 0.36 μM. Reprinted with 
permission from publisher.
[63]
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Figure 3.10 Inhibition of erythrocyte PKA activity in lysates using non-specific PKA inhibitors. 
Reprinted with permission from publisher.
[63]
 
 
Figure 3.11 Immunodepletion of PKA from erythrocyte lysates. Activity of erythrocytes pre-
cleared with a control anti-mouse IgG and lysates pre-cleared with an antibody against the catalytic 
subunit of PKA (a-b). Erythrocyte PKA levels (c-d) in lysates, lysates pre-cleared with a control anti-
mouse IgG, and lysates pre-cleared with an antibody against the catalytic subunit of PKA. Reprinted 
with permission from publisher.
[63]
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Temporal control using DMNB Atto-633 peptide. The GRTGRRFSY 
peptide was modified to contain a DMNB light cleavable group on the serine 
hydroxyl moiety, which prevents the serine from being phosphorylated until the 
DMNB is photocleaved by UV or 405 nm light. The light sensitive compound was 
determined to not be phosphorylated by PKA until illuminated with light both in 
buffer and in erythrocyte lysates (Figure 3.12).  
Figure 3.12 Photorelease  of Atto633-Aoc-GRTGRRFS(DMNB)Y. (a) Atto633-Aoc-
GRTGRRFS(DMNB)Y (1 μM) and Evans Blue (2 μM) in PBS buffer in the presence (black, 5 min) 
and absence (red) of illumination (365 nm for 10 min). PKA-catalyzed phosphorylation was initiated 
following illumination by the addition of PKA (10 nM).  (b) Atto633-Aoc-GRTGRRFS(DMNB)Y (1 μM) 
and Evans Blue (2 μM) in 10% erythrocyte lysate/PBS buffer upon illumination (365 nm, 5 min) in the 
absence (black, 5 min) and presence of KT5720 (green, 5 µM) and in the absence of illumination 
(red). PKA-catalyzed phosphorylation was initiated following illumination by the addition of ATP (1 
mM). Reprinted with permission from publisher.
[63]
 
 
Loading peptide and quencher into erythrocytes. To determine if PKA 
activity can be monitored within intact erythrocytes, the light-responsive peptide 
and quencher were loaded into erythrocytes. As described in Chapter 2 (Figure 
2.7a) and Figure 3.13 peptides can be loaded into erythrocytes and microscopy 
can be used to image fluorescence. Erythrocytes were subsequently loaded with 
peptide (Atto633-Aoc-GRTGRRFSY) and quencher (Evans Blue) and 
fluorescence was monitored by flow cytometry (Figure 3.14). Erythrocytes 
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loaded with peptide (Atto633-Aoc-GRTGRRFSY) display a bright fluorescence 
signal, while erythrocyte loaded with peptide (Atto633-Aoc-GRTGRRFSY) and 
quencher (Evans Blue) show reduced fluorescent signal indicating quencher and 
peptide associate in the erythrocytes.  
 
Figure 3.13 Confocal fluorescence images of Atto633-Aoc-GRTGRRFSY loaded peptides. 
Erythrocyte were loaded with Atto633-Aoc-GRTGRRFSY and imaged by confocal microscopy. 
Reprinted with permission from publisher.
[63]
 
 
 
 
Figure 3.14 Flow cytometry analysis of erythrocytes loaded with Atto633-Aoc-GRTGRRFSY 
peptide (red), Atto633-Aoc-GRTGRRFSY peptide and Evans Blue (green), and no loading 
control (blue). Reprinted with permission from publisher.
[63]
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Monitoring endogenous PKA activity in erythrocytes. Atto-633 
GRTGRRF(DMNB)SY (1 μM) was loaded into erythrocytes with Evans Blue (2 
μM). Activity was monitored by confocal fluorescence microscopy. 405 nm light 
was used to initiate the reaction in select cells. Figure 3.15a demonstrates that 
loaded erythrocytes display a fluorescent increase after photolysis, indicating 
phosphorylation. Similarly, in the presence of PKA inhibitor KT5720 or EDTA no 
fluorescence change is observed (Figure 3.15b). The fluorescent rings around 
the erythrocytes are most likely due to the negative charge associated with the 
erythrocyte membranes. The negatively charged quencher is unable to interact 
with the positively charged peptide at the erythrocyte membrane. 
Figure 3.15 Confocal images of Atto633-Aoc-GRTGRRFSY and Evans Blue loaded 
erythrocytes. Confocal images Atto633-Aoc-GRTGRRFSY and Evans Blue loaded erythrocytes (a) i 
before photolysis and ii 0.5, iii, 5 and iv 10 min after photolysis. Photolysis was performed with 50 
mW, 405 nm laser (2% power level) in tornado mode using a dwell time of 20 
Imaging was performed with a 100X objective using 635 nm at 4% laser power. Bar = 5 µm. (b) 
fluorescence fold change quantitated in confocal images black circles indicate peptide and quencher, 
white circles indicate not photolysis and black triangles indicate in the presence of cell permeable 
PKA inhibitor KT5720. Reprinted with permission from publisher.
[63]
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Discussion and Future Directions 
 Assays to monitor erythrocyte kinase activity could be used to elucidate 
erythrocyte signaling and potentially be used as a diagnostic disease marker. 
However, the ability to monitor kinase activity in erythrocytes is hindered due to 
the strong inner filter effect associated with high intracellular concentrations of 
hemoglobin, which while not evident through small cross sections such as a 
single red blood cell becomes exceedingly apparent in erythrocytes suspensions 
(figure 1.9). In order to overcome the inner filter effect we developed a 
fluorescent assay that uses red-shifted fluorophores (Figure 1-8). The developed 
assay uses a positively charged peptide that interacts with negatively charged 
quenchers. Upon PKA mediated phosphoryl transfer to the serine in the peptide, 
the overall charge of the peptide is decreased and the negatively charged 
quencher no longer interacts with the peptide, and a fluorescent increase is 
observed.  The method should be adaptable to other kinases as a sensor, 
provided that the recognized peptide sequence is positively charged. We initially 
screened a 48 member dye library, which covers a wide absorbance range, 
against two peptide sequences appended with various fluorophores on the N-
termini. The two peptide sequences selected were both previously reported to be 
recognized by PKA. [89, 90] All of the peptides we screened identified quenchers 
that provided robust fluorescent responses. The sequence GRTGRRFSY was 
selected for further optimization as the hits generally returned higher 
fluorescence increases after phosphorylation. The quencher that provided the 
most robust response in the absence of salt was Acid Blue 80, while in the 
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presence of salt, Evans Blue yielded better results. As a result, both quenchers 
were tested in the presence of erythrocytes to ensure the quenchers did not 
induce erythrocyte lysis. Evans Blue was selected as the quencher to use in 
further studies, as Acid Blue 80 induced significant lysis and had a lower affinity 
for the peptide. Erythrocytes have been previously demonstrated to contain 
significant amounts of PKA and its role PKA in erythrocytes has been implicated 
in controlling localized vasodilation through ATP release and also has been 
suggested to be important in erythrocyte phosphatidylserine (PS) flipping. With 
this in mind we first set about determining if erythrocyte PKA activity could be 
monitored in erythrocyte lysates. Figure 3.7 demonstrates that PKA activity can 
be monitored. Furthermore, as previously suggested, fluorophores that have 
excitation maximum that overlap with the hemoglobin absorbance experience a 
reduced signal. Atto633-Aoc-GRTGRRFSY was selected to be used in 
combination with Evans Blue for all PKA activity monitoring. As erythrocytes 
contain many other kinases, we set about demonstrating that our assay was 
specifically monitoring PKA activity in lysates. Inhibition of activity in the presence 
of PKA inhibitors H89 and KT5720 provided strong support that kinase activity is 
responsible for the fluorescence increase (Figure 3.9). Furthermore, activity was 
not inhibited in the presence of inhibitors that are not specific to PKA (Figure 
3.10). Lastly, clearing erythrocyte lysates of PKA using anti-PKA reduced the 
activity by an equal amount (Figure 3.11). These results provide strong evidence 
that the fluorescence activity observed in erythrocyte lysates is a result of PKA 
phosphorylation. In order to accomplish our goal of monitoring erythrocyte kinase 
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activity within loaded erythrocytes, we needed to establish control over when the 
substrate is susceptible to phosphorylation. Having previously demonstrated that 
light dependent photolysis of a nitobenzyl group can be accomplished using 
confocal microscopy (Chapter 2), we modified the peptide serine hydroxyl group 
with a dimethoxynitrobenyzl (DMNB) group. This group blocks phosphoryl 
transfer to the hydroxyl group. Indeed, in buffer and in lysates, no 
phosphorylation is observed in the absence of light (Figure 3.12).  Lastly, we 
demonstrated that our system can be loaded into erythrocytes using the method 
optimized in Chapter 2, and that upon illumination with 405 nm light, fluorescence 
activity is observed. By contrast, in the presence of KT5720, no fluorescence 
change is observed.  
 PKA activity is highly regulated and well understood in nucleated cells. 
However, PKA activity in erythrocytes remains largely under-studied. The assay 
developed in this chapter provides a way to fluorescently monitor real-time PKA 
activity in erythrocyte lysates. We found that erythrocytes stimulated with CPT-
cAMP, a cell permeable cAMP analog, contain many downstream proteins that 
experience dramatic increase in phosphorylation (Figure 3.14). Furthermore, PKA 
has been demonstrated to be localized to the membrane and the cytosol. Other 
stimulators of erythrocyte kinase activity such as sheer force, epinephrine, 
norepinephrine, or acetyl salicylic acid may provide selective stimulation to PKA 
activity.[91, 92] Our assay combined with proteomic and other physiological studies 
could be utilized to elucidate the role of PKA in erythrocytes. 
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Figure 3.14 Erythrocytes stimulated with DMSO H89 or CPT-cAMP then analyzed by 
western blot for phosphorylated PKA substrates. 
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CHAPTER 4: Erythrocyte Mediated Delivery of Anti-inflammatory 
Therapeutics 
 
 
OVERVIEW 
 
Controlling drug release with light provides a means of spatial and 
temporal control of its’ pharmacological activity. This, in turn, may help reduce 
unintended side effects associated with non-selective treatment.[2, 93] However, 
current technologies are limited to short wavelength (<450 nm) light or two 
photon absorption.  Short wavelength light is unable to sufficiently penetrate 
tissue (see Chapter 1), while two photon technology can only release drugs in a 
very small cross section and requires highly specialized equipment.  We have 
developed a strategy that utilizes cobalamin and a far-red fluorophore as an 
antenna for light capture and energy transfer to cobalamin. This enables the 
release of drugs from carriers within the optical window of tissue. Cobalamin-
drug conjugates and far-red fluorphores are appended to an octadecyl (C18) 
which acts to anchor the Cobalamin-drug conjugates to erythrocyte membranes. 
Analytical and cell based methods were used to demonstrate methotrexate, 
colchicine, and dexamethasone can be released from erythrocytes in a light 
dependent manner. 
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INTRODUCTION 
 
Currently, there are more than 1,500 FDA approved drugs.[2] However, 
this seemingly large number of therapeutics is not adequate to treat all known 
diseases.  Recently, it was estimated that there currently exist approximately 555 
genes in the human genome that encode proteins that could potentially serve as 
therapeutic drug targets. Furthermore, clinical trials are currently involved in 
targeting more than 85% of the known aforementioned targets. However, many 
of these clinical candidates will not pass efficacy and toxicity studies. When 
evaluating 108 failed clinical candidates 51% failed due to efficacy and 19% 
failed due to safety concerns.[94] Therapeutic efficacy and safety of these drugs 
can sometimes be improved by utilizing different delivery techniques. Improving 
drug delivery techniques has the potential to reduce side effects, undesirable 
immune responses, degradation and elimination while simultaneously improving 
bioavailability and targeted delivery.[2, 93]  Encapsulation of drugs within 
liposomes, micelles, nanoparticles, and erythrocytes has been purposed as a 
possible mechanism to improve bioavailability. Erythrocytes represent one of the 
most promising tools for reasons discussed in Chapter 1 and have been 
described as “champions of drug delivery”.[18]   
Using light to activate therapeutic agents is another method that can be 
used to reduce unintended side effects. Light dependent activation of these 
agents allows for temporal and spatial control. The therapeutic agents of interest 
93 
 
(photosensitizing agents) are targeted to cells of interest. Upon stimulation with 
light the photosensitizing agents produce cytotoxic reactive oxygen species that 
result in cell death.[41] One of the benefits of this procedure is that cells not 
targeted with light are not destroyed thereby reducing side effects. This minimally 
invasive procedure has been demonstrated to be successful in treating cancer 
while simultaneously reducing side effects.[41] However, this method is limited in 
scope to killing cells. Developing a general method to spatially control the release 
of drugs could provide a new line of treating cancer and other diseases such as 
diabetes, autoimmune diseases, or vascular diseases by targeting the specific 
site of disease. One of the largest hurdles in developing a therapy that can be 
released in a light dependent manner is developing a system that responds to 
light within the optical window of tissue. However, light between 600 and 950 nm 
is not able to provide enough energy to activate the pro-drugs described to 
date.[64] Others have attempted to circumvent this limitation by using two-photon 
technology or up converting nanoparticles (particles that absorb longer 
wavelength light and emit shorter wavelength light), but the challenges 
associated with these technologies (both have small absorption cross sections) 
hinder the extent of their current therapeutic applications.[95-97] 
We developed a method using alkylcobalamins that release anti-
inflammatory therapeutics using long wavelength light (>600 nm).[98] Cobalamins 
do not naturally absorb light above 570 nm. However, covalent modification of 
these species with far-red and near-IR fluorophores generates cobalamin 
derivatives that can both capture long wavelength light and use it to release 
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molecules from the weak Co-alkyl bond (<30 kcal/mol). We demonstrate using 
C18 modified far-red fluorophores and C18 modified cobalamin-drug conjugates 
localized to erythrocyte membranes, that transfer energy between the 
fluorophore and the cobalamin is sufficient to induce drug release. 
Our initial efforts have focused on photo-releasing anti-inflammatory 
agents. The treatment of inflammation in a localized region has the potential for 
excellent therapeutic enhancement over the current standard of care. 
Furthermore, erythrocytes are able to readily access areas of inflammation which 
will increase effectiveness of the drug release. Inflammation results in the 
destruction of tissue and involves migration of plasma, proteins, fluid, and 
leukocytes within the diseased area. Migration of proteins and small molecules 
leads to vasodilation and consequently an increased blood flow.[99] The 
aforementioned disruption in tissue homeostasis can result from bacterial 
infection or exposure to foreign particles.[100] Alternatively, altered immune 
response can lead to recognition of endogenous proteins and this can also lead 
to inflammation. We utilized three commonly prescribed anti-inflammatory 
compounds; methotrexate (rheumatoid arthritis), colchicine (gout), and 
dexamethasone (steroid based rheumatoid arthritis treatment) to demonstrate 
light dependent release of therapeutics from erythrocytes.  The three drugs were 
appended to the lipidated cobalamin and similarly a series of lipidated 
fluorphores were generated (Figure 4-1). The C18 moieties were appended to 
the 5ʹ ribose –OH of Cbl and drugs or fluorophores were attached to the Co via 
an amine or carboxylic acid handle. The synthesized compounds were then 
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added to erythrocytes and demonstrated, via analytical and cell based assays, to 
be inactive until the appropriate wavelength of light was used to photo release 
the anti-inflammatory drugs.  
 
 
 
Figure 4.1 Wavelength-encoded drug release strategy. a) Anti-inflammatory drugs are covalently 
appended to cobalamin (Cbl) via a weak photolabile Co-C bond. Lipidated Cbl and far-red/near-IR 
fluorophore constructs assemble on the plasma membrane of human erythrocytes. The fluorophore 
a) 
b) 
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serves as an antenna, capturing long wavelength light and transmitting it to the Cbl-drug, resulting in 
drug release from the erythrocyte carrier. b) Cbl-C18 derivatives anchored to erythrocyte membranes 
 
MATERIALS AND METHODS 
 
 Materials. Cyanocobalamin was purchased from Lalilabs Inc.  Alexa Fluor 
700 carboxylic acid, succinimidyl ester was purchased from Life Technologies.  
All other chemical reagents were purchased from Sigma Aldrich.  8x10 Color 
Film Gels were manufactured by MacNan and supplied by Amazon.  525 nm and 
660 nm LEDs were purchased from LED Supply.  725 nm and 780 nm LEDs 
were purchased from Techmark.  Erythrocytes were purchased from Allcells.   
 
 Synthesis (all compounds were synthesized by Zach Rodgers or Weston 
Smith. Synthetic steps have been included for clarity) 
 
Octadecylaminylcyanocobalamin. Cyanocobalamin (200 mg, 148 µmol, 
mw = 1355) was dissolved in 10 mL anhydrous DMSO and CDT (121 mg, 740 
µmol, mw = 164) was added. The solution was stirred for 45 min.  To this solution 
octadecylamine (398 mg, 1.48 mmol, mw = 269) was added to the rapidly stirring 
solution.  The resulting mixture was stirred for 1 h before being added to 90 mL 
either/chloroform.  The resulting precipitate was collected by centrifugation and 
decantation.  The pellet was dried under vacuum and 10 mL EtOH was added.  
Dimerized octadecylamine formed a white precipitate which was removed by 
centrifugation and the cobalamin was precipitated in 40 mL either/chloroform and 
collected by centrifugation and decantation.  The pellet was dissolved in EtOH 
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and purified on a 100 g Biotage KP-C18-HS flash column with a linear gradient 
an H2O:MeOH gradient from 0 – 100% in 8 column volumes.   
Octadecylaminylcyanocobalamin eluted at 100% MeOH.  Red solid, 75%, ESI 
MS calculated for C82H125CoN15O15P
- (M2+): m/z = 825.98, found 826.81. 
3-aminopropyloctadecylaminylcobalamin. The previous compound 
(100 mg, 61 µmol, mw = 1651) was dissolved in 10 mL of EtOH and degassed 
under nitrogen.  NH4Br (500 mg, 5% w/v) and Zn powder (200 mg, 3 mmol) were 
added and the solution was stirred for 20 min under nitrogen.  To this slurry 3-
chloropropylamine hydrochloride (40 mg, 305 µmol, mw = 130) was added.  The 
resulting mixture was stirred for 3 h under continuous nitrogen flow.  A color 
change from red to orange was observed.  Zinc was removed by centrifugation, 
and the cobalamin was recrystallized twice in either/chloroform (50 mL).  The 
resulting precipitate was collected by centrifugation and decantation.  The pellet 
was dried under vacuum and 10 mL EtOH was added.  UV-Vis analysis revealed 
the alkylation went to completion.  3-aminopropyloctadecylaminylcobalamin was 
purified on a 100 g Biotage KP-C18-HS flash column with a linear H2O:MeOH 
(0.1% TFA) gradient from 0 – 100% in 8 column volumes.   3-
aminopropyloctadecylaminylcobalamin eluted at 100% MeOH.  Orange solid, ESI 
MS calculated for C84H133CoN15O15P
- (M2+): m/z = 842.96, found 842.2. 
Octadecylaminocobalaminbutyrate. Octadecylaminylcyanocobalamin 
(100 mg, 61 µmol, mw = 1651) was dissolved in 10 mL of EtOH and degassed 
under nitrogen.  NH4Br (500 mg, 5% w/v) and Zn powder (200 mg, 3 mmol) were 
added and the solution was stirred for 20 min under nitrogen.  To this slurry 4-
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chlorobutryic acid (30 µL, 305 µmol, mw = 122, d = 1.24) was added.  The 
resulting mixture was stirred for 3 h under continuous nitrogen flow.  A color 
change from red to orange was observed.  Zinc was removed by centrifugation, 
and the cobalamin was recrystallized twice in either/chloroform (50 mL).  The 
resulting precipitate was collected by centrifugation and decantation.  The pellet 
was dried under vacuum and 10 mL EtOH was added.  UV-Vis analysis revealed 
the alkylation went to completion.  Octadecylaminocobalaminbutyrate was 
purified on a 100 g Biotage KP-C18-HS flash column with a linear gradient an 
H2O:MeOH (0.1% TFA) gradient from 0 – 100% in 8 column volumes.   
Octadecylaminocobalaminbutyrate eluted at 100% MeOH.  Orange solid, 82% 
yeild, ESI MS calculated for C85H133CoN14O17P
- (M2+): m/z = 855.95, found 
856.7. 
Methotrexate Octadecylaminylcobalamin (Cbl-MTX). Methotrexate (30 
mg, 66 µmol, mw = 454), N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU, 25 mg, 66 µmol, mw = 379), and N,N-
diisopropylethylamine (DIPEA, 58 µL, 332 µmol, mw = 129, d = 0.74) were 
dissolved in 5 mL of DMF and stirred for five min.  3-
aminopropyloctadecylaminylcobalamin (120 mg, 71 µmol, mw = 1681) was 
added and the solution was stirred overnight.  Because 3-
aminopropyloctadecylaminylcobalamin and Cbl-MTX cannot be separated by 
HPLC, 1,4,5,6,7,7-Hexachloro-5-norbornene-2,3 dicarboxylic anhydride (37 mg, 
185 µmol, mw = 370) was added.  The solution was stirred for 30 min and then 
frozen at -80 °C being careful not to thaw until just before purification.  Cbl-MTX 
99 
 
was purified on a Viva C4 preparative column 5 μm, 250 x 21.2 mm from Restek, 
H2O:ACN, 0.1% TFA, using a gradient elution (elution time 46 min), Orange solid, 
37%, ESI MS calculated for C104H153CoN23O19P
- (M2+): m/z = 1059.7, found 
1060.3; (M3+): m/z = 706.5, found 707.2. 
Synthesis of Colchicine octadecylaminylcobalamin (Cbl-COL). 
Octadecylaminylcyanocobalamin (63 mg, 37 µmol, mw = 1681), HBTU (10 mg, 
26 µmol, mw = 379), and DIPEA (15 µL, 86 µmol, mw = 129, d = 0.74)  were 
dissolved in 2 mL of DMF and stirred for 5 min.  Colchicine (10 mg, 28 µmol, mw 
= 1386) was added and the solution and was stirred overnight. Cbl-COL was 
purified on a Viva C4 preparative column 5 μm, 250 x 21.2 mm) from Restek, 
H2O:ACN, 0.1% TFA, gradient elution (elution time 35 min).  Orange solid, ESI 
MS calculated for C105H153CoN15O21P
- (M2+): m/z = 1025.0, found 1026.5; (M3+): 
m/z = 683.3, found 684.5. 
Synthesis of Dexamethasone succinyloctadecylaminylcobalamin 
(Cbl-DEX). Dexamethasone (6 mg, 12 µmol, mw = 492), HBTU (5 mg, 12 µmol, 
mw = 379), and TEA (10 µL, 57 µmol, mw = 129, d = 0.74) were dissolved in 1 
mL of DMF and stirred for 5 min.  3-aminopropyloctadecylaminylcobalamin (30 
mg, 18 µmol, mw=1681) was added and the solution was stirred overnight. Cbl-
DEX was purified on a Viva C4 preparative column 5 μm, 250 x 21.2 mm) from 
Restek, H2O:ACN, 0.1% TFA, using a gradient elution (elution time 62 min).  
Orange solid, ESI MS calculated for C110H164CoN15O22P
- (M2+): m/z = 1078.1, 
found 1079.3. 
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Synthesis of 5-TAMRA Octadecylaminylcobalamin (Cbl-TAM). 5-
Tetramethylrhodamine (TAMRA) (5 mg, 12 µmol, mw = 430), HBTU (4.5 mg, 12 
µmol, mw = 379), and DIPEA (8.3 µL, 48 µmol, mw = 129, d = 0.74) were 
dissolved in 5 mL of DMF and stirred for 5 min.  3-
aminopropyloctadecylaminylcobalamin (20 mg, 12 µmol, mw=1681) was added 
and the solution was stirred overnight.  Cbl-TAM was purified on a Viva C4 
preparative column 5 μm,250 x 21.2 mm) from Restek, H2O:ACN, 0.1% TFA, 
using a gradient elution (elution time 46 min).  Red solid, ESI MS calculated for 
C109H154CoN17O19P- (M2
+): m/z = 1047.5, found 1048.7; (M3+): m/z = 698.3, 
found 699.3. 
Syntehsis of 5-FAM Octadecylaminylcobalamin (Cbl-FAM). 5-
carboxyfluorecein (5-FAM, 5 mg, 12 µmol, mw = 430), TSTU (3.6 mg, 12 µmol, 
mw = 301), and DIPEA (8.3 µL, 48 µmol, mw = 129, d = 0.74) were dissolved in 5 
mL of DMF and stirred for 5 min.  3-aminopropyloctadecylaminylcobalamin (20 
mg, 12 µmol, mw = 1681) was added and the solution was stirred overnight.  Cbl-
FAM was purified on a Viva C4 preparative column 5 μm,250 x 21.2 mm) from 
Restek, H2O:ACN, 0.1% TFA, using a gradient elution (elution time 46 min).  
Orange solid, ESI MS calculated for C104H143CoN15O19P
- (M2+): m/z = 1020.0, 
found 1021.5; (M3+): m/z = 680.0, found 681.2. 
Synthesis of C18-AF700. Alexa Fluor 700 NHS Ester (1 mg, 1 µmol, mw 
= 1086),  DIPEA (5 µL, 29 µmol, mw = 129, d = 0.74), and C18 (5 mg, 19 µmol, 
mw = 269) were dissolved in 500 µL DMF and mixed by agitation overnight.  The 
resulting mixture was poured into 5:1 H2O:DCM mixture (5 mL).  The DCM layer 
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was washed with 4 mL H2O 3x.  Purified by flash chromatography silica column 
(30g).  MeOH:DCM (0.1% TFA) linear gradient 0-80%.  The purified lipidated 
fluorophore was concentrated by rotary evaporation. 
Synthesis of Cy5 and Cy7 dyes. Cy 5, Cy 7, N-(5-carboxypentyl)-2,3,3-
trimethyl indolium-5-sulfonate, and N-(3-sulfopropyl)-2,3,3-trimethyl indolium-5-
sulfonate were synthesized as previously described.[101]  
Synthesis of C18-Cy5. Cy 5 (6.2 mg, 12.8 μmol) and di-isopropyl 
carbodiimide (2.5 mg, 19.2 μmol) were dissolved in DCM (320 μL) and mixed for 
5 min. A solution of octadecylamine (6.9 mg) in chloroform (100 μL) was then 
added and the solution was allowed to react for 1 h. The solution was diluted with 
additional DCM (2 mL) and purified via silica gel elution using a binary solvent 
system (A: DCM, B: MeOH) with an initial A:B ratio of 90:10, gradually increasing 
to 1:4. Removal of solvent by rotary evaporation yielded a blue-viscous oil (74%, 
calculated from absorption, λmax: 646 nm) LC-MS ESI MS calculated for 
C50H76N3O
+ (M2+): m/z = 735.16, found 734.6 
Synthesis of C18-Cy7. Cy 7 (5.0 mg, 9.8 μmol) was coupled to 
octadecylamine similarly to the synthesis of Cy5-C18. Silica gel chromatography 
using the same A:B solvent gradient afforded a blue-green oil (95.2%, calculated 
from absorption, λmax: 760 nm) LC-MS ESI MS calc. for C52H78N3O
+ (M2+): m/z 
=760.61, found 760.6. 
Synthesis of Chloro-DY800. N-(5-carboxypentyl)-2,3,3-trimethyl 
indolium-5-sulfonate (300 mg, 850 μmol) and 3-chloro-2,4-
trimethyleneglutacondianil hydrochloride (305 mg, 850 μmol) were refluxed in a 
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solution of acetic acid/acetic anhydride (4 mL, 1:1 ratio) for 2 h. The solvent was 
then removed under reduced pressure and the residue was re-dissolved in a 
mixture of pyridine and acetic acid (4 mL, 1:1 ratio). N-(3-sulfopropyl)-2,3,3-
trimethyl indolium-5-sulfonate (325 mg, 850 μmol) was added and the solution 
was heated to 80 °C for 1 h. The product was then precipitated and washed 
thrice with ethyl acetate (100 mL). The blue precipitate was dissolved in water 
and eluted on a Biotage KP-C18-HS column using a binary solvent A:B solvent 
system (A: Water .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was 
gradually increased from an initial ratio of 19:1 to 2:3. Removal of the solvent by 
lyophilization yielded a green solid (180 mg, 25% yield, λmax: 794 nm) LC-MS ESI 
MS calclutated. for C39H45ClN2O11S32
- (M2+): m/z = 848.43, found 851.3 
Synthesis of DY800. Chloro-DY800 (100 mg, 120 μmol) was dissolved in 
anhydrous DMF (18 mL) to which was added a solution of sodium phenoxide 
(139 mg, 1.2 mmol) in DMF (1mL). The solution was stirred for 1 h, and then 
poured into a vigorously stirring solution of diethyl ether (250 mL). The precipitate 
was collected and then purified with a Biotage KP-C18-HS column using a binary 
solvent A:B solvent system (A: Water .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The 
A:B ratio was gradually increased from an initial ratio of 19:1 to 2:3. 
Lyophilization provided the product as a green solid (86 mg, 79% yield, λmax: 774 
nm). LC-MS ESI MS calculated for C45H49N2O12S33
-(M2+): m/z = 906.07, found 
909.2 
Synthesis of C18-DY800. DY800 (2.0 mg, 2.2 μmol) and HCTU (1.4 mg, 
3.3 μmol) were dissolved in anhydrous DMF (500 μL) and allowed to activate for 
103 
 
5 min. A 500 μL solution of octadecylamine in chloroform (1 mg/mL) was added 
and the solution was then mixed for 1 h. The product was extracted into aqueous 
solution by washing of the organic solution with water (2 x 1 mL). The aqueous 
phase was then purified by HPLC using a stationary C4 phase with a A:B solvent 
system (A: Water .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was 
gradually increased from 10:1 to 1:19. The solvent was removed by rotary 
evaporation to give a blue-green oil (35% yield, λmax: 776 nm in ethanol). LC-MS 
ESI MS calculated for C63H87N3O11S32
- (M2+): m/z = 1158.57, found 1160.6 
 
Quantitation of methotrexate release. 75 µL samples of MTX 
suspended in 1x PBS containing 1 mM MgCl2 were injected onto an 1200 series 
Agilent HPLC with a UV-Vis detector, 1260 infinity fluorescent detector, and 6110 
quadrapole mass spectrometer from a 384 well plate.  The mobile phase 
consisted of H2O:ACN (0.1% FA) (gradient provided in the following table).  The 
column used was a Viva C4 analytical column 5 μm, 50 x 21.2 mm from Restek.  
Concentrations were determined by taking the area under UV absorbance trace 
at 300 nm from 3.1-3.7 min where the Cbl-MTX cleavage products were shown 
to elute and this integration was compared to known standards.  Mass cutoff was 
450 daltons.  Fluorescent detector λex 365 nm λem 470 nm to detect known 
products of light degradation.   
 
Quantitation of colchicine release 75 µL samples of colchicine 
suspended in 1x PBS containing 1 mM MgCl2 were injected onto an 1200 series 
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Agilent HPLC with a UV-Vis detector, 1260 infinity fluorescent detector, and 6110 
quadrapole mass spectrometer from a 384 well plate.  The mobile phase 
consisted of H2O:ACN (0.1% FA) (gradient provided in the following table).  The 
column used was a Viva C4 analytical column 5 μm, 50 x 21.2 mm from Restek.  
Concentrations were determined by taking the area under UV absorbance trace 
at 365 nm from 4.3-4.8 min where the Cbl-COL cleavage products were shown to 
elute and this integration was compared to known standards.  LC gradient is 
given in the MTX LC-MS Assay. 
 
Quantitation of dexamethasone release. 120 µL samples of 
dexamethasone suspended in 1x PBS containing 1 mM MgCl2 were boiled for 10 
min to denature and precipitate any protein and lipids in solution.  Protein was 
then pelleted by centrifugation at 21,000 rcf.  Samples of 75 µL were injected 
onto a 1200 series Agilent HPLC with a UV-Vis detector, 1260 infinity fluorescent 
detector, and 6110 quadrapole mass spectrometer from a 384 well plate.  The 
mobile phase consisted of H2O:ACN (0.1% FA) (gradient provided in Table S2).  
The column used was a Viva C4 analytical column 5 μm, 50 x 21.2 mm from 
Restek.  Concentrations were determined by taking the area under UV 
absorbance trace at 239 nm from 4.5-4.9 min where the Cbl-DEX cleavage 
product was shown to elute and this integration was compared to known 
standards.  LC gradient is given in the MTX LC-MS Assay. 
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Octanol / water partition MTX. Cbl-MTX was added to 100 μl octanal to 
a final concentration of 5 μM and was thoroughly mixed with 1x PBS (500 µL) in 
a 1.5 mL clear centrifuge tube and allowed to equilibrate for 30 min in the dark 
before undergoing centrifugation for 10 min at 21,000 g.  Samples were 
photolyzed with a 525 nm LED for 0 min, 1 min, 2 min, 5 min, 10 min, and 20 min 
before being mixed by shaking and allowed to equilibrate for 15 min.  This was 
followed by a 10 min centrifugation at 21,000 g.  The octanol layer was removed 
and 100 µL aliquots were taken from the remaining aqueous layer and loaded 
onto a 384 well plate.  The concentrations of was determined by the MTX LC-MS 
assay. 
 
Octanol / water partition TAMRA. Cbl-TAM was added to 100 μL octanal 
to a final concentration of 10 µM and was thoroughly mixed with 1x PBS (300 µL) 
in a 1.5 mL clear centrifuge tube and allowed to equilibrate for 30 min in the dark 
before undergoing centrifugation for 10 min at 21,000 g in a quartz fluorescence 
cuvette with a 200 µL viewing window.  The fluorescence of the aqueous layer 
was measuring using a PTI Model 710 LPS-220 (ex: 555 nm em: 570-600 nm).  
The solution was transferred to a clear 1.5 mL centrifuge tube and photolyzed 
using a 525 nm centered LED array for 0 min, 1 min, 2 min, 3 min, and 10 min.  
The solutions were transferred back to the cuvette for 10 min centrifugation at 
21,000 g and the fluorescence was measured again.  All samples were 
measured in triplicate. 
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Erythrocyte sample preparation and storage. Erythrocytes were 
washed 3x in 1x PBS containing 1 mM MgCl2 and diluted to 10% hematocrit.  
Storage was in RBC Buffer (1x PBS, 1mM MgCl2) for one no more than month at 
4°C. 
   
Erythrocyte loading procedure. To 10% hematocrit erythrocytes, 
lipidated compounds were added at various loading concentrations (depending 
on the assay). The erythrocytes were then incubated at RT for 20 min and 
subsequently washed 3x in 1x PBS containing 1 mM MgCl2 and then stored at 
10% hematocrit in RBC buffer.  RBCs were used within 48 h. 
 
Widefield microscopy with Cbl-TAM loaded erythrocytes. 10% 
hematocrit erythrocytes were loaded with 10 μM Cbl-TAM using the erythrocyte 
loading procedure. 2 μL of loaded erythrocytes were then added to 200 μL RBC 
buffer and imaged using widefield microscopy. Images were taken using 20 μs 
exposure times and a Cy3 filter cube 333 ms apart.   
 
Erythrocyte lysis assay.  To a 1.5 mL centrifuge tube containing 100 µL 
of a cobalamin drug complex (Cbl-MTX, Cbl-COL, or Cbl-DEX) in PBS at various 
concentrations (5 µM, 10 µM, 20 µM, and 40 µM) was added 100 µL RBCs in 
RBC buffer (10% hematocrit).  Three additional samples contained 100 µL RBCs 
treated with 100 µL PBS.  Three samples contained 0.1% SDS before RBCs 
were added.  Final concentrations were 0.05% SDS; 0 µM, 2.5 µM, 5 µM, 10 µM, 
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and 20 µM lipidated complex.   Cells were mixed by flicking before centrifugation 
at 300 g for 30 min. Samples were re-homogenized and allowed to incubate at 4 
oC overnight. Samples were pelleted at 1000 g for 5 min. 150 µL of the 
supernatant was plated on a 96 well plate and analyzed at 550 nm by UV Vis.  
SDS samples had to be diluted 10 fold to be measured accurately.  SDS 
absorbance multiplied by 10 was considered to be complete hemolysis and PBS 
treated blood was considered to be completely intact and the absorbance from 
those samples was subtracted from the background of the rest.   
 
Erythrocytes drug loading capacity. Using the erythrocyte loading 
procedure different concentration of Cbl-MTX, Cbl-COL, and Cbl-DEX were 
added to 10% hematocrit RBCS. Cbl-MTX was loaded at 6 µM, 4 µM, 2 µM, and 
1 µM.  Cbl-COL was loaded at 10 µM, 8 µM, 6 µM, 4 µM, and 2 µM.  The cells 
were diluted to 5% hematocrit and photolyzed for 2 h under 525 nm centered 
LEDs and then spun down at 1000 g.  Concentration was quantitated by LC-MS. 
 
DHFR inhibition assay. Dihydrofolate reductase activity was monitored 
using the Sigma Dihydrofolate Reductase Assay Kit. This kit was used to monitor 
conversion of NADPH to NADP+. Briefly, assay buffer was prepared containing 
1.5 mU DHFR, 100 μM NADPH, and 1x assay buffer (provided with kit). Inhibition 
of DHFR activity at various concentrations MTX or photolyzed Cbl-MTX (between 
100 nm and 5 μM) was monitored using a fluorescent plate reader (Ex: 340 nm 
Em: 450 nm).  
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(Cell work completed by Robert Hughes) 
Colchicine HeLa cell assay. HeLa cells were plated in a 6-well glass 
bottom plate (Mattek) at a density of 1.5 x 105 cells per well and maintained at 37 
ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% 
FBS, 1% Pen-Strep). The following day, cells were treated with colchicine (Sigma 
C9754; 1 mM stock in DMSO) or DMSO for either 30 min or 1 h at 37 ºC in a 
humidity-controlled incubator. At the conclusion of the incubation period, cells 
were fixed with 1 mL of methanol at room temperature for 10 min. Cells were 
washed 2x 1 mL with PBS and blocked for 1 h in 5% Donkey Serum. Blocking 
was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody 
(Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% 
Triton-X-100; PBS). Cells were then washed with PBS (3x 5 min) before 
incubation with anti-mouse AlexaFluor 488 secondary antibody (Life 
Technologies A21202) at 1:500 dilution in antibody dilution buffer. After washing 
cells with PBS (3x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 40X phase contrast 
objective and a FITC filter cube (Semrock). Metamorph software was employed 
for imaging analysis. 
 
Treatment of HeLa cells with Cbl-COL loaded erythrocytes. HeLa cells 
were plated in 24-well glass bottom plates (Mattek) at a density of 3.3 x 104 cells 
per well and maintained at 37 ºC in a humidity-controlled incubator with a 5% 
CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells 
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were washed 2x with PBS, followed by the addition of 100 μL of L-15 media. 
Cells were then treated with 250 μL of a suspension of Cbl-COL loaded red blood 
cells in PBS (6 μM loading concentration at 5% hematocrit) or 250 μL PBS 
(control cells). Cells were then either kept in the dark at 37 ºC in a humidity-
controlled incubator, or exposed to 530 nm LED flood light (PAR38; 500 – 570 
nm emission; 5 mW power) for 5, 10, or 20 min at room temperature. All cells 
incubated for 1 h in a 37 ºC in a humidity-controlled incubator post-photolysis.  At 
the conclusion of the incubation period, cells were washed 3 x 1 mL with PBS 
and then fixed with 1 mL of methanol at room temperature for 10 min. Cells were 
washed 2 x 1 mL with PBS and blocked for 1 h in 5% Donkey Serum. Blocking 
was followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody 
(Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% 
Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before 
incubation with anti-mouse AlexaFluor 488 secondary antibody (Life 
Technologies A21202) at 1:500 dilution in antibody dilution buffer. After washing 
cells with PBS (3x 5 min), images were acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 40X phase contrast 
objective and a FITC filter cube (Semrock). Metamorph software was employed 
for imaging analysis. 
 
Treatment of HeLa cells with dexamethasone. HeLa cells were plated 
in a 6-well glass bottom plate (Mattek) at a density of 7.5 x 104 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 
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atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were 
treated with varying concentrations of dexamethasone (1 mM stock in DMSO) or 
DMSO for 1 h at 37 ºC in a humidity-controlled incubator. At the conclusion of the 
incubation period, cells were fixed with 4% PFA in PBS for 10 min at room 
temperature, then washed 1x with PBS, and then treated with 1 mL of methanol 
at room temperature for 5 min. Cells were washed 2 x 1 mL with PBS and 
subsequently incubated overnight at 4 ºC with rabbit anti-GRα antibody (abcam 
3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; 
PBS). Cells were then washed with PBS (3 x 5 min) before incubation with anti-
rabbit AlexaFluor 488 secondary antibody (Life Technologies A21206) at 1:500 
dilution in antibody dilution buffer for 1 h at room temperature. Cells were washed 
with PBS (3 x 5 min) and Hoescht 33342 (100 μg/mL in PBS) applied for 30 min 
before an additional wash with PBS. images were subsequently acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 
40X phase contrast objective and a FITC filter cube (Semrock). Metamorph 
software was employed for imaging analysis. 
 
Treatment of HeLa cells with Cbl-DEX loaded erythrocytes. HeLa cells 
were plated in 12-well glass bottom plates (Mattek) at a density of 2.5 x 104 cells 
per well and maintained at 37 ºC in a humidity-controlled incubator with a 5% 
CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells 
were washed 2x with PBS, then treated with 500 μL of a suspension of Cbl-DEX 
loaded red blood cells in L-15 media (1 μM loading concentration at 5% 
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hematocrit) or 500 μL L-15 (control cells). Cells were then either kept in the dark 
at 37 ºC in a humidity-controlled incubator, or exposed to 530 nm LED flood light 
(PAR38; 500 – 570 nm emission; 5 mW power) for 10, 20, or 30 min at room 
temperature. All cells incubated for 1 h in a 37 ºC in a humidity-controlled 
incubator post-photolysis.  At the conclusion of the incubation period, cells were 
washed 3 x 1 mL with PBS and then fixed with 4% PFA in PBS for 10 min at 
room temperature, then washed 1x with PBS and  treated with 1 mL of methanol 
at room temperature for 5 min. Cells were subsequently washed 2 x 1 mL with 
PBS and then incubated overnight at 4 ºC with rabbit anti-GRα  antibody (abcam 
3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; 
PBS). Next, cells were washed with PBS (3 x 5 min) before incubation with anti-
rabbit AlexaFluor 488 secondary antibody (Life Technologies A21206) at 1:500 
dilution in antibody dilution buffer for 1 h at room temperature. Cells were finally 
washed with PBS (3 x 5 min). Images were subsequently acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 
40X phase contrast objective and a FITC filter cube (Semrock). Metamorph 
software was employed for imaging analysis. 
 
Demonstrating TAMRA and fluorescein release from erythrocyte 
membranes upon photolysis. Erythrocytes were taken from 10% hematocrit 
stock solutions.  RBCs were loaded with 1 µM Cbl-TAM or Cbl-FAM according to 
the established procedure.  For those experiments requiring lipidated 
fluorophores, 5 µM were also loaded from stock solutions in DMSO.   
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Erythrocytes were re-suspended to 10% hematocrit and exposed to LEDs 
centered at varying wavelengths for set time points.  After photolysis, the 
erythrocyte solution was centrifuged at 1,000 g and the supernatant was 
analyzed for TAMRA (Ex: 550 nm Em: 580 nm) or fluorescein (Ex: 492 nm Em: 
519 nm) release using a fluorescent plate reader.  
 
Cbl-DEX light independent translocation test. HeLa cells were plated in 
6 well glass bottom plates (Mattek) at a density of 8.8 x 104 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 
atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were 
washed 2x with PBS, then treated with 250 μL of a suspension of Cbl-DEX 
loaded red blood cells in L-15 media (1 μM loading concentration at 5% 
hematocrit) or 250 μL L-15 (control cells). Cells were then incubated in the dark 
for 1 h at 37 ºC in a humidity-controlled incubator. After the 1 h pre-incubation, 
cells were washed 3x 1 mL with PBS (dark room; red safe light) and 2 mL of L-15 
added to each well.  The washed cells were then exposed to a green LED light 
source (PAR38; 500 – 570 nm emission; 5 mW power) or kept in the dark for 15 
min at room temperature. All cells incubated for 1 h in a 37 ºC in a humidity-
controlled incubator post-photolysis.  At the conclusion of the second incubation 
period, cells were washed 3x 1 mL with PBS and then fixed with 4% PFA in PBS 
for 10 min at room temperature, then washed 1x with PBS and treated with 1 mL 
of methanol at room temperature for 5 min. Cells were subsequently washed 2x 
1 mL with PBS and then incubated overnight at 4 ºC with rabbit anti-GRα  
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antibody (abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 
0.3% Triton-X-100; PBS). Next, cells were washed with PBS (3 x 5 min) before 
incubation with anti-rabbit AlexaFluor 488 secondary antibody (Life Technologies 
A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room temperature. 
Cells were finally washed with PBS (3x 5 min). Images were subsequently 
acquired with an inverted Olympus IX81 microscope equipped with a 
Hamamatsu C8484 camera, 40X phase contrast objective and a FITC filter cube 
(Semrock). Metamorph software was employed for imaging analysis. 
 
Determining the ratio of Cbl-TAM to C18-Cy5 for optimal release of 
Tetramethylrhodamine. To 10% hematocrit erythrocytes, various 
concentrations of Cbl-TAM (0 to 10 μM) and various concentrations of C18-Cy5 
were added (0 to 20 μM). Erythrocytes were photolyzed using a 660 nm LED 
board for 30 min. After photolysis, erythrocytes were spun down at 1,000 g for 3 
min and the supernatant was analyzed for tetramethylrhodamine (Ex: 550 Em: 
580) release using a fluorescent plate reader. 
            〈
μmol photons
   
〉  
〈
 
  
〉
             
  
 
Light power measurements. All light measurements were recorded with 
a Coherent Field Max II. Each measurement is reported as the average of 10 
readings and the error is reported as the standard deviation. The measurements 
were recorded using the same distance and light configurations as the samples. 
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Confocal images of erythrocytes loaded with C18-Cy5. To 10% 
hematocrit erythrocytes C18-Cy5 was loaded at a concentration of 5 μM using 
the erythrocyte loading procedure.  2 μL of loaded erythrocytes were then added 
to 200 μL RBC buffer and imaged using confocal microscopy. Images were taken 
using 4% laser power, 1000 hν, and 10 μs/pixel in line scan mode and a 635 nm 
laser. 
 
Methotrexate NIR photolysis from erythrocyte membranes. Cbl-MTX 
and either C18-Cy5, C18-AF700, C18-Cy7, C18-DY800 were loaded with a 
concentration of 1 μM and 5 μM respectively to 10% hematocrit erythrocytes.  
After the loading erythrocytes were re-suspended to 5% hematocrit and exposed 
to 660 nm, 725 nm, or 780 nm centered LEDs 30 min.  Other loaded erythrocytes 
were photolyzed for 2 h using 525 nm LEDs to free all bound MTX to assess the 
total amount of drug loaded.  After photolysis, the erythrocyte solution was 
centrifuged at 1,000 g and the supernatant was analyzed for by the methotrexate 
LC/MS assay. 
 
Dexamethasone and colchicine NIR photolysis from erythrocyte 
membranes. Cbl-COL (loading concentration of 5 μM) or Cbl-DEX (final 
concentration of 0.5 μM) were loaded with either C18-DY800 or C18-Cy5 
fluorophore to 10% hematocrit erythrocytes. C18-DY800 was added to a final 
concentration of 5 and 2.5 μM for the Cbl-COL and Cbl-DEX erythrocytes 
respectively.  C18-Cy5 was added to a final concentration of 25 and 2.5 μM for 
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the Cbl-COL and Cbl-DEX erythrocytes respectively. Erythrocytes were re-
suspended to 5% hematocrit. The C18-DY800 samples were exposed to 525 nm 
LEDs for 2 h or 780 nm LEDs for 0 and 30 min and the C18-Cy5 were exposed 
to 525 nm and 660 nm LEDs in similar fashion.  After photolysis, the erythrocyte 
solution was centrifuged at 1,000 g and the supernatant was analyzed for Col or 
Dex release by LC/MS.  Baseline was determined by analyzing erythrocyte 
lacking the cobalamated drugs. 
 
Treatment of HeLa cells with Cbl-DEX /C18-Cy5 loaded erythrocyrtes. 
HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 
x 105 cells per well and maintained at 37 ºC in a humidity-controlled incubator 
with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following 
day, cells were washed 3x with PBS, then treated with 200 μL of a suspension of 
Cbl-DEX /C18-Cy5 (0.5 μM / 2.5 μM) loaded red blood cells in L-15 media (5% 
hematocrit) or 200 μL L-15 (control cells). The cells were either kept in the dark 
or exposed to a 660 nm LED array for 10, 20, or 30 min using the appropriate 
filter sets. All cells were placed in a 37 ºC in a humidity-controlled incubator post-
photolysis until harvest 1 h after the end of the last photolysis interval.  Cells 
were washed 3 x 1 mL with PBS and then fixed with 4% PFA in PBS for 10 min 
at room temperature, then washed 1x with PBS and treated with 1 mL of 
methanol at room temperature for 5 min. Cells were subsequently washed 2 x 1 
mL with PBS and then incubated overnight at 4 ºC with rabbit anti-GRα antibody 
(abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-
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X-100; PBS). Next, cells were washed with PBS (3x 5 min) before incubation with 
anti-rabbit AlexaFluor 488 secondary antibody (Life Technologies A21206) at 
1:500 dilution in antibody dilution buffer for 1 h at room temperature. Cells were 
finally washed with PBS (3 x 5 min). Images were subsequently acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 
60X oil objective and a FITC filter cube (Semrock). Metamorph software was 
employed for imaging analysis. 
 
Treatment of HeLa cells with Cbl-COL /C18-Cy5 loaded erythrocytes. 
HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 
x 105 cells per well and maintained at 37 ºC in a humidity-controlled incubator 
with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following 
day, cells were washed 3x with PBS, then treated with 200 μL of a suspension of 
Cbl-COL/C18-Cy5 (5 μM/25 μM) loaded red blood cells in L-15 (5% hematocrit) 
or 200 μL L-15 (control cells). Cells were then either kept in the dark at 37 ºC in a 
humidity-controlled incubator, or exposed to a 660 nm LED array for 10, 20, or 30 
min using the appropriate filter sets. All cells incubated for 1 h in a 37 ºC in a 
humidity-controlled incubator post-photolysis.  At the conclusion of the incubation 
period, cells were washed 3x 1 mL with PBS and then fixed with 1 mL of 
methanol at room temperature for 10 min. Cells were washed 2x 1 mL with PBS 
and blocked for 1 h in 5% donkey serum. Blocking was followed by overnight 
incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 
1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
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Cells were then washed with PBS (3x 5 min) before incubation with anti-mouse 
AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 dilution 
in antibody dilution buffer. After washing cells with PBS (3x 5 min), images were 
acquired with an inverted Olympus IX81 microscope equipped with a 
Hamamatsu C8484 camera, 60X oil objective and a FITC filter cube (Semrock). 
Metamorph software was employed for imaging analysis. 
 
Treatment of HeLa cells with Cbl-COL/DY800 loaded erythrocytes. 
HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 
x 105 cells per well and maintained at 37 ºC in a humidity-controlled incubator 
with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following 
day, cells were washed 3x with PBS, then treated with 200 μL of a suspension of 
Cbl-COL/DY800 (5 μM/5 μM) loaded red blood cells in L-15 (5% hematocrit) or 
200 μL L-15 (control cells). Cells were then either kept in the dark at 37 ºC in a 
humidity-controlled incubator, or exposed to a 660 nm LED array for 10, 20, or 30 
min using the appropriate filter sets. All cells incubated for 1 h in a 37 ºC in a 
humidity-controlled incubator post-photolysis.  At the conclusion of the incubation 
period, cells were washed 3x 1 mL with PBS and then fixed with 1 mL of 
methanol at room temperature for 10 min. Cells were washed 2x 1 mL with PBS 
and blocked for 1 h in 5% donkey serum. Blocking was followed by overnight 
incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 
1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Cells were then washed with PBS (3 x 5 min) before incubation with anti-mouse 
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AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 dilution 
in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were 
acquired with an inverted Olympus IX81 microscope equipped with a 
Hamamatsu C8484 camera, 60X oil objective and a FITC filter cube (Semrock). 
Metamorph software was employed for imaging analysis. 
 
CETSA assay of HeLa cells treated with Cbl-MTX loaded 
erythrocytes. HeLa cells were plated in 12-well tissue culture plates at a density 
of 9.4 x 104 cells per well and maintained at 37 °C in a humidity-controlled 
incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The 
following day, cells were washed 3x with PBS, then treated with 300 μL of a 
suspension of Cbl-MTX loaded red blood cells in L-15 (5 μM methotrexate 
loading concentration at 5% hematocrit), 300 μL L-15 (control cells), or 300 μL L-
15 with 10 μM methotrexate (positive control). Cells were then either kept in the 
dark at 37 °C in a humidity-controlled incubator, or exposed to a green LED light 
source (PAR38; 500 – 570 nm emission; 5 mW power) for 10, 20, or 30 min. At 
the end of the photolysis interval, all cells were incubated for 1 h in a 37 °C in a 
humidity-controlled incubator.  Next, cells were washed 3x 1 mL with PBS and 
trypsinized with 300 μL 0.05% Trypsin (Gibco) for 5 min at 37 °C. Trypsinized 
cells were then pelleted (5 min, 2000 rpm, 4 °C), washed 1 x 300 μL PBS, and 
then pelleted again. After removal of the supernatant, cell pellets were heated at 
52 °C in a temperature controlled heat block for 3 min, and then cooled for 3 min 
at room temperature. 30 μL of lysis buffer (25 mM Tris HCl/2 mM DTT/1X Pierce 
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HALT protease and phosphatase inhibitor) was added to each pellet, which were 
then subjected to 2 freeze-thaw cycles in liquid N2. The resulting solutions were 
then spun at 17000 g from 20 min at 4 °C. The resulting supernatants were 
removed and combined with 6X LSB-BME and boiled for 4 min at 95 °C, then 
analyzed by western blot (Overnight incubation at 4 °C  with Santa Cruz anti-
DHFR E18 primary antibody( 1:1000 in TBST/5%BSA) and Cell Signaling anti-
GAPDH antibody (1:2000), followed by incubation with the appropriate secondary 
antibodies. 
 
RESULTS 
 
 Water-octanol demonstration of release from cobalamin. The water-
octanol experiment seeks to mimic the layer between the erythrocyte membrane 
and the surrounding buffered solution. To demonstrate that the Cbl-C18 
derivatives stay in the octanol (lipid-like) layer until illumination, TAMRA-Cbl-C18 
and MTX-Cbl-C18 were incubated in octanol and mixed with PBS buffer. After 
illumination both TAMRA (Figure 4.2) and MTX (Figure 4.3) were observed in 
the aqueous layer.  
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Figure 4.2 Fluorescent fold change in aqueous fraction after photolysis. Fluorescence increase 
in aqueous fraction after photolysis of TAMRA-Cbl-C18. Reprinted with permission from the 
publisher.
[102]
 
 
Figure 4.3 Transfer of methotrexate to aqueous layer after photolysis. % transfer of 
methotrexate after photolysis of MTX-Cbl-C18 to aqueous layer. Reprinted with permission from the 
publisher.
[102]
 
 
 Demonstration of TAMRA and FAM release from erythrocyte 
membranes. To demonstrate proof of concept that our Cbl-C18 constructs 
stayed in the erythrocyte membrane until photolysis we used TAM-Cbl-C18 and 
FAM-Cbl-C18. FAM and TAM are fluorescence reporters that are easily 
visualized by plate readers. After photolysis with 525 nm light, the samples were 
centrifuged and the supernatant was monitored for fluorescence of TAM and 
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FAM respectively.  We demonstrated (Figure 4.4) that TAM and FAM were 
released from erythrocyte membranes only upon illumination with 525 nm light. 
The concentration of TAM and FAM released in the supernatant increased as the 
photolysis time increased. 
Figure 4.4 Monitoring FAM and TAM release after fluorescence in erythrocyte supernatants. 
Erythrocytes were loaded with either TAM-Cbl-C18 (open circles) or FAM-Cbl-C18 (closed circles) 
and photolyzed using 525 nm light. Fluorescence was monitored in the supernatant after centrifuging 
and reported with the background subtracted of the no loading control. 
 
 Optimization of NIR release of TAMRA from erythrocyte membranes. 
To determine the optimal ratio of fluorophore-C18 to Drug-Cbl-C18 needed to 
see sufficient release (as characterized by observed fluorescence signal), 
various concentrations of TAM-Cob-C18 and Cy5-C18 were incubated with 
erythrocytes. The erythrocytes were illuminated with 660 nm light the supernatant 
122 
 
was then analyzed for TAMRA release by fluorescence spectroscopy. Although 
significant release was observed at many ratios (Figure 4.5 and Figure 4.6), 5 
μM fluorophore-C18 and 1 μM TAM-Cbl-C18 was selected as the optimal ratio 
for most future studies. The values reported in Figure 4.5 and Figure 4.6 
represent the concentration of TAMRA released as determined by fluorescence 
with the background (no loading control) subtracted out. However, where higher 
concentrations of Drug-Cbl-C18 was needed to see biological activity, the 
concentration of the fluorophore-C18 were kept constant and only the 
concentration of the Drug-Cbl-C18 was increased to the necessary levels. 
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Figure 4.5 TAMRA release (fluorescence fold increase) as a function of Cy5-C18 and TAM-Cbl-
C18. TOP: Fluorescence increase in supernatant after photolysis no Cy5-C18 (dark), 10x Cy5-C18 
(grey) 100x Cy5-C18 (white). BOTTOM: Erythrocytes were mixed with various concentrations of Cy5-
C18 and TAM-Cbl-C18 then washed and illuminated with 660 light. TAMRA release was monitored in 
the supernatant by fluorescence (Ex 550 nm Em 550 nm). Circles represent maximum (top left) and 
minimum (bottom right) fluorescence fold changes. 
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Figure 4.6 Concentration of TAMRA released at 660 nm using various concentrations of Cy-5 
C18 and 1 μM TAM-Cbl-C18. Erythrocytes were mixed with various concentrations of Cy5-C18 and 
1 μM TAM-Cbl-C18 then washed and illuminated using 660 nm light (525 nm light as a positive 
control). Concentration of TAMRA released was measured in the supernatant as determined by 
fluorescence.  
 
  
Release using NIR light is accomplished using co-localized C18 
modified fluorophores.  We co-loaded erythrocytes with TAM-Cbl-C18 or FAM-
Cbl-C18 and either Cy5-C18, AF700-C18, Cy7-C18, or FL800-C18. Loaded 
erythrocytes were then illuminated with LED boards corresponding to the 
excitation of the fluorophore-C18 conjugates. In the absence of Fluorphore-C18 
no TAMRA release is observed (Figure 4.7). We demonstrated (Figure 4.8 and 
Figure 4.9) that upon illumination of the ‘antenna’ fluorophore at its excitation 
wavelength TAM or FAM release from the erythrocyte membrane. 
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Figure 4.7 Ratio of TAMRA released in the absence of fluorophore-C18 after photolyzing at the 
fluorophor-C18 corresponding excitation maximum. Erythrocytes were mixed with 1 μM TAM-
Cob-C18 and 5 μM of the Fluorophore-C18. TAMRA release was quantitated after 30 min photolysis 
at the corresponding wavelengths. 
 
Figure 4.8 Concentration of TAMRA released using various fluorophore-C18 after photolyzing 
at their corresponding excitation maximum. Erythrocytes were mixed with 1 μM TAM-Cob-C18 
and 5 μM of the Fluorophore-C18. TAMRA release was quantitated using fluorescence (no loading 
control as background) after 30 min photolysis at the corresponding wavelengths. 
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Figure 4.9 Concentration of Fluorescein released using various fluorophore-C18 after 
photolyzing at their corresponding excitation maximum. Erythrocytes were mixed with 1 μM 
FAM-Cob-C18 and 5 μM of the Fluorophore-C18. Fluorescein release was quantitated after 30 min 
photolysis at the corresponding wavelengths. 
 
 Microscopy imaging of loaded erythrocytes. Confocal microscopy was 
used to assess the distribution of fluorophore-C18 loaded erythrocytes. The 
disruption of loading was found to be uniform (Figure 4.10). Similarly, widefield 
microscopy (significantly faster acquisition times) was used to image TAM-Cbl-
C18 loaded erythrocytes. Although imaging TAMRA induced rapid release from 
the erythrocytes, it was determined that the TAMRA is evenly distributed 
amongst the RBCs (Figure 4.11). 
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Figure 4.10 Confocal images of erythrocytes loaded with Cy5-C18. Cy5-C18 (5 μM) was added 
to 10% hematocrit erythrocytes. Following incubation and washing erythrocytes were plated at 0.1% 
hematocrit and imaged by confocal microscopy. Left; phase contrast, Middle; Cy-5 fluorescence, 
Right; Overlay, white bar indicates 5 μm. Reprinted with permission from the publisher.
[102]
 
 
 
 
Figure 4.11 Release of TAMRA from the erythrocytes membrane into the surrounding medium 
visualized by widefield microscopy. TAM-Cbl-C18 (5 μM) was added to 10% hematocrit 
erythrocytes. Following incubation and washing erythrocytes were plated at 0.1% hematocrit and 
imaged by confocal microscopy. Left; brightfield, Middle to right; TAM fluorescence, white bar 
indicates 5 μm. Reprinted with permission from the publisher.
[102]
 
 
 Anti-inflammatory drug release from erythrocyte membranes.  The 
anti-inflammatories have a minimal impact on erythrocyte lysis as determined by 
monitoring hemoglobin in the supernatant (<10%) when using 5 μM MTX-CBL-
C18, DEX-CBL-C18 or COL-CBL-C18. MTX-CBL-C18, DEX-CBL-C18, and COL-
CBL-C18 were loaded onto erythrocytes. Erythrocytes were illuminated with 525 
nm light and subsequently the samples were centrifuged and the supernatants 
analyzed by LC-MS for the presence of the anti-inflammatory agents. The 
amount of drug release correlated with the amount loaded onto the erythrocytes 
(Figure 4.12). 
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Figure 4.12 Correlation between amount of Drug-Cbl-C18 loaded onto erythrocytes and 
concentration of Drug released into the supernatant. Erythrocytes were loaded with Col-Cbl-C18 
(orange), MTX-Cbl-C18 (blue), and Dex-Cbl-C18) at various concentrations. After loading was 
completed concentration of release was measured by LC/MS after photolysis.  Reprinted with 
permission from the publisher.
[102]
 
 
 Testing biological activity of released anti-inflammatories. To 
demonstrate the release of drugs has an impact on biological activity MTX-Cbl-
C18, and Col-Cbl-C18 were photolyzed independently and tested for biological 
activity. The photolyzed MTX demonstrated inhibition of DHFR (Figure 4.13). 
Lastly, photolyzed colchicine induced the expected depolymerization of 
microtubules (Figure 4.14).   
Figure 4.13 Inhibition of DHFR using methotrexate (circles) and photo-MTX (triangles). DHFR 
inhibition was monitored in the presence of various concentrations of commercially source 
methotrexate and photolyzed MTX-CBL (photo-MTX refers to the photolyzed cbl-MTX product). 
Reprinted with permission from the publisher.
[102]
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Figure 4.14 Photolyzed colchicine added to HeLa cells. Photolyzed Col-CBL-C18 was titrated into 
HeLa cell culture before the cells were fixed and stained for tubulin to visualize microtubule networks.  
At around 2 µM colchicine the networks are disrupted and lamellapodia are truncated as microtubules 
aggregate chaotically at their fringes. Reprinted with permission from publisher.
[102]
 
 
 Release of anti-inflammatories from erythrocytes. MTX-Cbl-C18, Dex-
Cbl-C18, and Col-Cbl-C18 were individually incubated with erythrocytes. After 
incubation and washing, the different drug-carriers were exposed to HeLa cells 
and illuminated (or incubated in the dark) with 525 nm light. As before, GRα 
translocation was observed only upon illumination in the presence of Dex-Cbl-
C18 (Figure 4.15). Depolymerization of microtubules was observed upon 
illumination with 525 nm light and not observed in the dark samples in the 
presence of Col-Cbl-C18 (Figure 4.16). The CETSA assay (measures amount of 
drug bound protein by measuring remaining protein in supernatant after 
heating)[103] was used to demonstrate methotrexate was delivered to cells and as 
observed in Figure 4.17, methotrexate delivery is only observed in the presence 
of 525 nm light. 
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Figure 4.15 Hela cells exposed to dexamethasone.  a)  DMSO treated HeLa cells b) HeLa cells 
treated with 250 nm dexamethasone (commercially sourced).  c)  HeLa cells were treated with RBCs 
loaded with 1 µM Cbl-DEX no photolysis.  d) HeLa cells were treated with RBCs loaded with 1 µM 
Cbl-Dex-C18 with photolysis.  HeLa cells were stained with Alexa488 antiRabbit/anti-Gralpha (green) 
and DAPI (blue). Reprinted with permission from publisher.
[102]
 
 
.
Figure 4.16 Hela cells exposed to Col-Cbl-C18 loaded erythrocytes.  a)  20 min photolysis at 525 
nm, b) dark, c) no erythrocytes in the dark, d) no erythrocytes 20 min photolysis 525 nm light. Col-
Cbl-C18 loaded erythrocytes were added to HeLa cell culture and photolyzed. The cells were fixed 
and stained for tubulin to visualize microtubule networks. Reprinted with permission from 
publisher.
[102]
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Figure 4.17 Cellular thermal shift assay of HeLa cells treated with MTX-Cbl-C18 loaded 
erythrocytes.  In the absence of MTX no MTX bound DHFR is detected (no treatment).  HeLa cells 
treated with MTX-Cbl-C18 and not exposed to light contain minimal MTX bound DHFR as evidenced 
by no observable band in the dark lane using anti-DHFR. After 30 min of photolysis significant MTX 
bound DHFR is present. Photolysis was carried out by 525 nm centered LEDs. Reprinted with 
permission from publisher.
[102]
 
 
 NIR light release of anti-inflammatories from erythrocytes. MTX-Cbl-
C18, Dex-Cbl-C18, and Col-Cbl-C18 were individually incubated with 
erythrocytes and Cy7-C18, FL800-C18, and Cy5-C18, respectively. After 
incubation and washing, each of the erythrocytes were exposed to HeLa cells 
and illuminated (or incubated in the dark) with 725 nm, 780 nm, 660 nm, light 
respectively, corresponding to the excitation wavelengths of the antenna. As 
before, when DexCbl-C18 and Cy5-c18 are introduced to erythrocytes, GRα 
translocation was observed only upon illumination with 660 nm light (Figure 
4.18). When Col-Cbl-C18 and FL800-C18 are introduced to erythrocytes, 
depolymerization of microtubules was observed upon illumination with 780 nm 
light and not observed in the dark samples (Figure 4.19). The CTSA assay was 
used to demonstrate methotrexate was delivered to cells and as observed in 
Figure 4.20, methotrexate delivery is only observed in the presence of 725 nm 
light. 
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Figure 4.18 Widefield images HeLa cells after dexamethasone release from Dex-Cbl-C18 
and Cy5-C18 loaded erythrocytes using 660 nm light. a) Untreated HeLa cells.  b) HeLa cells 
treated with RBCs loaded with 1 µM Dex-Cbl-C18 in the absence of light.  c) HeLa cells treated 
with RBCs loaded with 1 µM Dex-Cbl-C18 and photolyzed at 780 nm for 15 min.  Cells were 
visualized using Alexa488 antiRabbit/anti-GRα (green) and Dapi (blue). Reprinted with 
permission from publisher.
[102]
 
 
133 
 
Figure 4.19 Widefield images HeLa cells after colchicine release from COL-Cbl-C18 and 
FL800-C18 loaded erythrocytes using 780 nm light. a) untreated HeLa cells.  b) HeLa cells 
treated with RBCs loaded with 5 µM Col-Cbl-C18 in the absence of light.  c) HeLa cells treated 
with RBCs loaded with 5 µM Col-Cbl-C18 and photolyzed with 780 nm light for 15 min.  The cells 
were fixed and stained for tubulin to visualize microtubule networks. Reprinted with permission 
from the publisher.
[102]
134 
 
 
Figure 4.20 Cellular thermal shift assay of HeLa cells treated with MTX-Cbl-C18 and Cy7-
C18 loaded erythrocytes  HeLa cells treated with MTX-Cbl-C18 in the absence of light have 
minimal MTX bound DHFR after 30 mins of photolysis with 725 nm light significant MTX bound 
DHFR is present. Photolysis was carried out by 725 nm centered LEDs. Reprinted with 
permission from publisher.
[102]
 
 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 A light mediated drug delivery system could provide a general method to 
reduce side effects due to interactions of therapeutics with unintended targets. 
As such, we sought to develop a light mediated method for therapeutic agents 
that operate within the optical window of tissue. Using vitamin B12 derivatives 
(cobalamin) known to be photoresponsive at wavelengths less than 600 nm, our 
lab had previously demonstrated that modifying the 5ʹ hydroxyl of ribose with 
fluorophores that have excitation maximum in the optical window of tissue will 
induce cleavage of the Co-C bond at the excitation wavelength of the 
fluorophore. We hypothesized that simply localizing fluorophores and the 
cobalamin derivatives to membranes would allow for sufficient cross-talk 
between the fluorophore and the cobalamin to induce release at the fluorophore 
excitation wavelengths. To test our hypothesis we created a series of lipidated 
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fluorophores and lipidated cobalamin conjugates. Our initial efforts focused on 
release of fluorophores TAMRA and Fluoroscein from lipidated cobalamin.  
 Initially we confirmed that following photolysis of TAM-Cbl-C18 and MTX-
Cbl-C18 translocation of TAM and MTX from octanol to an aqueous buffer is 
observed (confirming our C18 derivatives prefer to remain in a non-polar 
environment until photolysis). We next determined fluorophores could be release 
in such a manner from erythrocyte membranes. Our results, shown in Figure 4.4, 
demonstrate, using 525 nm light, the release of both TAM and FAM from 
erythrocytes membranes. Furthermore, in the presence of 660 nm light no 
fluorophore is released. Next, we wanted to determine if adding a fluorophore 
with an excitation maximum near 660 would allow for light mediated release at 
660 nm. Our results, shown in Figure 4.5, demonstrate TAM is released under 
these conditions. However, the ratio of TAM-Cbl-C18 to Cy5-C18 was unsuitable 
for general adaptation to other systems. Therefore, we tested a wide range of 
TAM-Cbl-C18 (0 to 10 μM) and Cy5-C18 (0 to 20 μM) concentrations. Figure 4.5 
reveals that although a wide range of ratios induce significant TAM release at 
660 nm, using 5 μM Cy5-C18 and 1 μM TAM-Cbl-C18 furnishes significant 
release with a minimal excess of Cy5-C18. We therefore decided that for all 
future studies 5 μM fluorophore-C18 would be used to promote the release of 
drugs of interest to maintain minimal concentration of exogenous lipid added to 
the membrane, even if excess drug-Cbl-C18 was needed to elicit a response. 
Cy5-C18 was also shown to promote the release FAM from cobalamin. We next 
sought to determine if Alexa Fluor 700, Cy7, and a far-red fluorophore we call 
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FL800 could also induce release of TAM and FAM from Cbl-C18.We 
demonstrated, Figure 4.9 and Figure 4.9, each fluorophore-C18 induces 
significant release of TAM and FAM with minimal loss in the absence of light.  
Our findings provided us with proof of concept. We subsequently sought to 
apply the technology toward the release of anti-inflammatory agents. Anti-
inflammatory agents are represented by a broad class of chemical entities and 
often elicit harmful side effects. As inflammation is highly localized, using our 
system to spatially and temporally deliver anti-inflammatory agents could 
potentially reduce the side effects associated with systemic delivery. Our choice 
of anti-inflammatory drugs is more specifically based on their role in the 
treatment of rheumatoid arthritis (RA). RA therapies generally require frequent 
and long-term drug systemic administration, which commonly results in increased 
risk of severe side effects. For example, the nearly 50% of RA patients who are 
dependent upon glucocorticoids, such as dexamethasone, experience weight 
gain, osteoporosis, diabetes mellitus, hypertension, skin fragility and infections 
(infections arising from being systemically immunocompromised).[104, 105] As a 
result, there is significant demand for the development of therapeutics that can 
be selectively delivered to arthritic joints.[106-108] We tested our technology on 
commonly used anti-inflammatory agents. We first synthesized methotrexate, 
dexamethasone, and colchicine Cbl-C18 derivatives. We subsequently 
determined that Cbl-MTX, Cbl-Col and Cbl-Dex can be loaded onto erythrocyte 
membranes at concentrations up to 5 μM with minimal damage to the 
erythrocyte. Furthermore, the concentration of drug-loaded and subsequent 
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photolysis released a predictable amount of drug. Photolysis of the Co--
CH2CH2CH2Drug bond primarily, but not exclusively, generates the alkyl product 
CH3CH2CH2Drug. We photolyzed MTX-Cbl and demonstrated inhibition of 
dihydrofolate reductase (DHFR) using a commercially available DHFR assay kit 
(Figure 4.13).  As expected, based on previous reports of the structure activity 
relationship of MTX derivatives, the photolyzed product of Cbl-MTX is an 
effective inhibitor of dihydrofolate reductase.[109] N-colchicine butyramide as the 
photolyzed erythrocyte-loaded Cbl-COL was identified by LC-MS to be the 
primary product. N-colchicine butyramide was determined to be an inhibitor as 
effective as native colchicine of microtubules in HeLa cells (Figure 4.14). 
Photolysis of Cbl-DEX-loaded erythrocytes produces three products (1, X = CH3, 
CH2OH, CHO) and are known prodrugs that are hydrolyzed to DEX upon cellular 
uptake.[110, 111] To demonstrate the impact of dexamethasone on HeLa cells, 
HeLa cells were exposed to commercially available dexamethasone and showed 
the expected nuclear translocation of GRα (Figure 4.15).  Having established 
biological activity of the released anti-inflammatories we wanted to demonstrate 
that our drug-Cbl-C18 derivatives could be released from erythrocytes at 525 nm 
and that release could be tuned to wavelengths in the optical window of tissue. 
As expected, erythrocytes loaded with each individual drug produced the desired 
cellular responses using the dexamethasone and colchicine assays previously 
described and the cellular thermal shift assay (CETSA) was used to determine if 
methotrexate bound DHFR in HeLa cells (Figure 4.15, Figure 4.16, and Figure 
4.17). We then co loaded erythrocytes with Cy5-C18 and Dex-Cbl-C18 and 
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demonstrated that photolysis in the presence of 660 nm light led to nuclear 
translocation of GRα. Furthermore, in the absence of Cy5-C18 migration of GRα 
did not occur. Similarly, microtubule depolymerization only occurred after 
illumination by 760 nm light when Col-Cbl-C18 was co-loaded with FL800-C18 
into erythrocyte. MTX binding to DHFR, as determined by CTSA, at 725 nm 
occurred only in erythrocytes co-loaded with Cy7-C18. 
We report the development of long-wavelength photo-responsive drug 
release constructs that are able to be tuned to the optical window of tissue. We 
demonstrated that anti-inflammatory release is able to be tuned to other 
wavelengths based on the excitation properties of the fluorophores. Our strategy 
uses erythrocytes since their long half-life and negligible immunogenic response 
ideally positions them as carriers. Additionally, this strategy could be extended to 
other carrier systems such as liposomes or nanoparticles.  
 
  
139 
 
 
 
 
CHAPTER 5: Final Thoughts and Future Directions 
 
Overview 
 
My dissertation research has sought to address the utility of erythrocytes 
for studying intracellular enzymatic activity with potential for use as diagnostic 
agents and as a tool for localized delivery of anti-inflammatory therapeutics. The 
key findings of my research are that 1) erythrocytes can be loaded, using 
hypotonic dilution, with small molecules, peptides, and fluorophore labeled PKA . 
2) Erythrocytes can be loaded with UV light response photocleaving groups. 3) 
Erythrocyte PKA activity can be monitored using confocal microscopy and a light-
controlled kinase assay. 4) Erythrocytes can be ‘decorated’ with drug-cobalamin 
(Drug-Cbl) derivatives that can be tuned to release drugs using light within the 
optical window of tissue. In the final chapter of this dissertation the focus will be 
on the future directions in which this technology can be applied. 
  
Erythrocytes as carriers  
 
As discussed throughout this dissertation, erythrocytes represent an 
excellent prospect for drug and diagnostic agent delivery. This lab’s future 
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objectives for erythrocyte based drug delivery is to 1) optimize erythrocyte based 
delivery systems, 2) increase the affinity of the Drug-Cbl conjugates to the 
membrane by using more hydrophobic anchors and 3) load drug-Cbl into 
erythrocytes and demonstrate release.  
Anchoring therapeutics to erythrocyte membranes. Through our research, 
it was demonstrated that C18 is sufficient to anchor certain constructs to 
erythrocyte membranes. However, exchange of lipids between membranes has 
been demonstrated since the 1960s.[112] The lipid exchange rate is dependent on 
the association constant of the lipid with membrane bilayer and is a function of 
the hydrophobic nature of the lipid. Increasing the lipid hydrophobicity may 
increase the association of the lipid drug-Cbl conjugates and reduce membrane 
exchange. As a demonstration of lipid membrane exchange erythrocytes were 
loaded with either Cy5-C18 or TAMRA-C18 and separately washed as described 
in Chapter 4. The erythrocytes were then mixed together and imaged using 
confocal microscopy. As observed in Figure 5.1 and Figure 5.2, the mixture of 
the two erythrocytes contained cells loaded with both Cy5 and TAMRA and cells 
loaded with TAMRA alone. This indicates TAMRA-C18 is exchanging between 
membranes. Cy5-C18 did not appear to exchange as readily and may be a 
function of the increased hydrophobic nature of the fluorophore. However, it has 
been reported that use of a phospholipid is sufficient to anchor cyanine dyes to 
erythrocyte membranes, even in the presence of serum or in mice.[113-116] 
Therefore, we propose to use phospholipids that contain more hydrophobic tails 
such as phosphotidylcholine or phosphotidylserine (Figure 5.3). These 
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phospholipids will also have the added benefit that they are more biologically 
relevant and should reduce risk of eliciting an immune response. Identifying 
phospholipids that increase the association of the Drug-Cbl derivatives for the 
membrane could have a two-fold benefit: 1) The increased association will 
enhance compatibility with biologically relevant system where the presence of 
serum becomes problematic. 2) Enhanced compatibility could allow for 
orthogonal control over drug-release. In an ideal system, erythrocytes could be 
loaded with DrugA-Cbl-lipid complex in the presence of FluorophoreC-C18. 
Other erythrocytes could be loaded with DrugB-Cbl-Lipid in the presence of 
FluorophoreD-C18 and then illuminating using FluorophoreC excitation would 
only release DrugA while illuminating with FluorophoreD excitation would furnish 
release of DrugB. In the current system (reported in Chapter 4), exchange 
between the membranes would dramatically reduce our ability to control drug 
release orthogonally; thus facilitating the need for a new lipid anchor.  
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Figure 5.1 Confocal images of erythrocyte loaded with Cy5-C18 and TAMRA-C18. Erythrocytes 
were loaded with 5 μM TAMRA-C18 or 5 μM Cy5-C18 then mixed. The sample was imaged by 
confocal microscopy. 
 
 
Figure 5.2 Overlay of Cy5-C18 and TAMRA-C18 loaded erythrocytes mixed together.
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Figure 5.3 Chemical Structure of phosphatidylcholine (left), phosphatidylethanolamine 
(middle), and phosphatidylserine (right). 
 
Loading therapeutics into erythrocytes. An alternative method to anchoring 
therapeutic agents to the outside of erythrocytes is to load them into 
erythrocytes. This method has been demonstrated using dexamethasone to treat 
ulcerative colitis and L-asparaginase to treat acute lymphoblastic leukemia 
(ALL).[117, 118] However, dexamethasone loading uses diffusion as a method of 
drug release and L-asparaginase is active within the circulating erythrocytes and 
is unable to escape erythrocytes as such, neither of these methods are able to 
be spatially controlled. We propose loading erythrocytes with Drug-Cbl 
derivatives. Using this design cobalamin would localize the drug to the 
erythrocyte interior. After photolysis the drug should be able to rapidly diffuse 
through the lipid bilayer. As erythrocyte pore formation, including size after 
resealing, can be affected by the loading procedure, the loading procedure could 
be optimized to allow for drugs to rapidly exit the cells (including drugs that are 
not able to diffuse through the membrane). As a proof of concept, erythrocytes 
were loaded with a Bodipy-Cbl derivative that releases bodipy (membrane 
permeable fluorescent membrane marker) at 660 nm light. We were able to 
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follow bodipy release from erythrocytes using fluorescence spectroscopy and 
confocal microscopy (Figure 5.4 and Figure 5.5). This method provides several 
obvious advantages over systemic administration and even over our current 
membrane anchoring technology. Loading the drug into erythrocytes completely 
removes the possibility that the drugs could be modified by extracellular 
proteases or other proteins involved in metabolism. This method eliminates the 
need to identify fluorophores that can be modified to contain a lipid anchor and 
as a result all commercially available fluorphores become a potential antenna to 
control drug release. Lastly, loading the conjugates into the erythrocytes also 
ensures orthogonal control of drug release. Two batches of erythrocytes, 
containing different drugs with different fluorophores, can be simultaneously 
loaded and mixed. The desired drug could be released with the corresponding 
fluorophore excitation wavelength. Future studies will involve the use of other 
therapeutic agents in combination with commercially available red fluorophores.
Figure 5.4 Fluorescence increase in supernatant of bodipy loaded erythrocytes in the 
presence and absence of light (660 nm). 
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Figure 5.5 Erythrocytes loaded with Bodipy-Cbl and imaged by confocal microscopy. Top; 
confocal images captured every 6 s of bodipy fluorescence; final frame represents fluorescence after 
1 min. Bottom; normalized fluorescence loss of bodipy containing erythrocytes from top figure. 
 
Other carriers (hybrid erythrocytes nano-vesicles, nanoparticles, 
liposomes/micelles).  
 
Although erythrocytes represent an excellent source of drug delivery 
vesicles they are not the only ones. Other types include ‘manufactured’ carriers; 
such as, hybrid erythrocyte nano-vesicles,[119] nanoparticles,[120] and liposomes or 
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micelles.[121] Each of these manufactured carriers has several advantages and 
disadvantages as compared to erythrocyte carriers. While immunogenicity can 
be a problem with each method, one of the primary advantages of these methods 
is that size can be controlled. This could allow for delivery to tissue outside the 
reach of erythrocytes which are unable to pass through vessels less than 3 μm in 
diameter or through the vessel wall and directly to the diseased tissue. 
Furthermore, as these delivery vehicles are manufactured in the lab they are 
easy to append with targeting agents. As an example, nanoparticles can be 
formulated to contain doxorubicin and targeting by appending antibodies towards 
a particular cancer target.[122] Indeed, this method was demonstrated to increase 
uptake and cytotoxicity in a human carcinoma cell line.[123] Synthesizing 
nanoparticles that contain a cancer cell targeting agent and a cobalamin-
chemotherapeutic could provide targeted delivery in a temporal manner. This 
could significantly reduce side effects of chemotherapy treatments and could 
increase treatment success by increasing the concentration of the therapeutic at 
the cancerous site.  
 
Using cobalamin to control enzymatic activity. 
 
 Lastly, using all of the strategies outlined through this dissertation, we 
could create an assay to monitor protein kinase activity in real time using light 
that operates within the optical window of tissue. As depicted in Figure 5.6, 
erythrocytes can be loaded with a peptide-Cbl-lipid moiety, free quencher, and 
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lipidated quencher. Upon photolysis of the construct, the peptide would be 
released into the cytosol and in the absence of phosphorylation would remain 
quenched. In the presence of active enzyme a fluorescence increase would 
occur due to phosphorylation. This could be used to study erythrocyte kinase 
activity and more importantly could be used to study how these enzymes 
respond to external stimuli such as sheer stress, low oxygen, or exposure to 
nitric oxide. 
Figure 5.6 Schematic representation for long wavelength control to measure erythrocyte 
kinase activity in real time 
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